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Background: West Africa Ebola Outbreak
Largest ever recorded – Ebola (Zaire) virus
 >2,000 cases since March, >1000 deaths
 First outbreak in West Africa: Guinea, Liberia, Sierra 
Leone, Nigeria
CDC Emergency Operations Center activated, 
staff and numerous international personnel 
deployed 
 Clinical Care, Data Management, Epidemiology, Health 
Education & Communications, Laboratory diagnostics
Ebola and Marburg Hemorrhagic Fevers:
The Viruses
Family Filoviridae
 5 species of Ebolavirus
• Zaire ebolavirus (1976)= Ebola virus
• Sudan ebolavirus (1976)= Sudan virus
• Reston ebolavirus (1989)= Reston virus
• Taï Forest ebolavirus (1994)= Tai Forest virus
• Bundibugyo ebolavirus (2007)= Bundibugyo virus
 1 species of Marburgvirus
• Marburgvirus marburgvirus (1967)

Filovirus Ecology
• Marburg: reservoir is Egyptian Fruit Bats 
(Rousettus aegyptiacus)
• Exposures to cave-dwelling bats
• Ebola: Reservoir is UNKNOWN
• Bats implicated
• Non-Human primates also develop severe 
hemorrhagic disease
• Duikers, pigs (Reston)– can become infected, 
role of transmission unknown
Zoonotic Transmission
• Direct contact (slaughter, consumption) of 
infected animals:
• Bats (are a possible source of infection)
• Primates
• Environmental exposure
• Entering caves, buildings infested with bats
Virus Inactivation
• 1:10 Bleach solution
• 5% Hospital-grade Lysol / phenolics
• Micro-Chem / quaternary ammonium
• Incineration / Autoclave
• Virus labile to desiccation and UV
Clinical Manifestations- Humans
• Incubation period: 2–21 days
• Abrupt onset
• Fever, headache, chills, malaise, and myalgia
• GI symptoms most common: vomiting, diarrhea, 
abdominal pain
• Hemorrhagic symptoms in <half of cases
• Mild: petechiae, epistaxis, ecchymosis, bruising
• Severe: GI hemorrhage, shock, DIC
• Less commonly seen: rash (trunk, shoulders), 
conjunctivitis, pharyngitis, cough, hiccups
Course of Disease & Virus shedding
• Not transmissible prior to onset of symptoms
• All body fluids (blood, urine, saliva, feces etc.) can carry 
virus
• Virus quantity increases to death, usually 9-10 
days post-onset of symptoms
• If patient survives to day 14, increased chance of 
survival








IgM: up to 3 – 6 months
ELISA IgG
IgG: up to 3 – 5 years (life-long persistance?)
days post onset of symptoms
RT-PCR
Critical information: Date of onset of fever/symptoms
Laboratory Diagnosis
Fever
Days 3 to 10
 Appropriate test depends on the timing of the 
sample (diagnostic testing is useless unless 
there are symptoms present)
 Blood and sera are best specimens for 
testing in live patients
 Tissues (spleen, liver, skin snips) may be 
tested if patient is deceased.
 Oral swabs can also be used in extreme 
circumstances but is not recommended for 
routine testing (not as sensitive, shorter 
window for positives, etc)
General Laboratory Diagnostics
 Please note, diagnostic testing is useless unless 
there are symptoms present (Testing in the 
absence of symptoms is dangerous)
 General diagnostic tests (some require special 
facilities):
 Molecular detection – RT-PCR and Real-time 
RT-PCR (detects virus)
 Ideally on specimens from days 3 to 10 post-onset of symptoms
 Viral isolation* – only in BSL4 laboratory
 Antigen ELISA (detects virus)
 IgM ELISA (detects early antibody)
 IgG ELISA (detects late antibody)
General Laboratory Diagnostics
Diagnostic Shipping Guidelines
• PLEASE CONTACT THE CDC EOC 
• +1-770-488-7100
• Eocevent246@cdc.gov
• 4 mL serum, plasma, or whole blood
• Shipped refrigerated on ice pack or frozen on dry 
ice (no glass tubes)
• IATA guidelines; triple-packaging
• UN 2814 “Suspected Category A Infectious 
Substance”
Case Definition for Ebola Virus Disease (EVD)
Updated: August 22, 2014
Early recognition is critical for infection control. Health care providers should be alert for and 
evaluate any patients suspected of having Ebola Virus Disease (EVD).
Person Under Investigation (PUI)
A person who has both consistent symptoms and risk factors as follows:
1. Clinical criteria, which includes fever of greater than 38.6 degrees Celsius or 101.5 degrees 
Fahrenheit, and additional symptoms such as severe headache, muscle pain, vomiting, 
diarrhea, abdominal pain, or unexplained hemorrhage; AND
2. epidemiologic risk factors within the past 21 days before the onset of symptoms, such as 
contact with blood or other body fluids or human remains of a patient known to have or 
suspected to have EVD; residence in—or travel to—an area where EVD transmission is 
active*; or direct handling of bats or non-human primates from disease-endemic areas.
Probable Case
A PUI whose epidemiologic risk factors include high or low risk exposure(s) (see below)
Confirmed Case
A case with laboratory-confirmed diagnostic evidence of Ebola virus infection
Exposure Risk Levels
Levels of exposure risk are defined as follows:
High risk exposures
A high risk exposure includes any of the following:
• Percutaneous (e.g., needle stick) or mucous membrane exposure to blood or body fluids of 
EVD patient
• Direct skin contact with, or exposure to blood or body fluids of, an EVD patient without 
appropriate personal protective equipment (PPE)
• Processing blood or body fluids of a confirmed EVD patient without appropriate PPE or 
standard biosafety precautions
• Direct contact with a dead body without appropriate PPE in a country where an EVD 
outbreak is occurring*
Low risk exposures
A low risk exposure includes any of the following
• Household contact with an EVD patient
• Other close contact with EVD patients in health care facilities or community settings. Close 
contact is defined as 
a. being within approximately 3 feet (1 meter) of an EVD patient or within the patient’s 
room or care area for a prolonged period of time (e.g., health care personnel, household 
members) while not wearing recommended personal protective equipment (i.e., standard, 
droplet, and contact precautions; see Infection Prevention and Control 
Recommendations (/vhf/ebola/hcp/patient-management-us-hospitals.html))
b. having direct brief contact (e.g., shaking hands) with an EVD case while not wearing 
recommended personal protective equipment.
• Brief interactions, such as walking by a person or moving through a hospital, do not constitute 
close contact
No known exposure
Having been in a country in which an EVD outbreak occurred within the past 21 days and having 
had no high or low risk exposures
As of 22 August 2014, countries with EVD outbreaks are Guinea, Liberia, and Sierra Leone. There are also cases of EVD in 
Lagos, Nigeria. For more information about specific districts where the EVD outbreak is occurring, visit: 
www.cdc.gov/vhf/ebola/outbreaks/guinea/ (/vhf/ebola/outbreaks/guinea/index.html)
For purposes of monitoring and movement restrictions of persons with Ebola virus exposure, low risk is interpreted as 
some risk. See www.cdc.gov/vhf/ebola/hcp/monitoring-and-movement-of-persons-with-exposure.html
(/vhf/ebola/hcp/monitoring-and-movement-of-persons-with-exposure.html)
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Web-links for Information on Ebola Hemorrhagic fever 
[Contact CDC EOC for official guidance on Ebola: Eocevent240@cdc.gov] 
Fact sheets: 
CDC Fact sheet: http://www.cdc.gov/vhf/ebola/index.html  
WHO fact sheet: http://who.int/mediacentre/factsheets/fs103/en/  
Case definitions: 
Case definition CDC: http://www.cdc.gov/vhf/ebola/hcp/case-definition.html  




WHO Risk assessment: 
http://who.int/csr/disease/ebola/EVD_WestAfrica_WHO_RiskAssessment_20140624.pdf?ua=1  
Public awareness documents 
http://www.cdc.gov/vhf/ebola/outbreaks/guinea/print-resources.html 
HAN: 
Health Alert Network (HAN):  Recent HAN; HAN 364; HAN 365; HAN 366; HAN 367 
                                                                                            
Laboratory diagnosis: 
Diagnostic information CDC: http://www.cdc.gov/vhf/ebola/diagnosis/index.html  
CDC Sample collection guidelines: http://www.cdc.gov/vhf/ebola/hcp/interim-guidance-specimen-collection-
submission-patients-suspected-infection-ebola.html  
Form for specimen submission with in the US:   http://www.cdc.gov/ncezid/dhcpp/vspb/specimens.html  
 http://www.cdc.gov/ncezid/dhcpp/vspb/pdf/specimen-submission.pdf  
Reference Laboratories: 
1) CDC, Atlanta GA, USA 
2) Pasteur Institute, Lyon, France 
3) BNI Hamburg, Germany   
4) National Microbiology Laboratory, Winnipeg, Canada 
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• Infection Control for Collecting and Handling Specimens
• Specimen Handling for Routine Laboratory Testing (not for Ebola Diagnosis)
• When Specimens Should Be Collected for Ebola Testing
• Preferred Specimens for Ebola Testing
• Storing Clinical Specimens for Ebola
• Diagnostic Testing for Ebola Performed at CDC
• Transporting Specimens within the Hospital / Institution
• Packaging and Shipping Clinical Specimens to CDC
• Occupational Health
• When to Contact CDC
• Additional Resources and Information
Interim Guidance for Specimen Collection, Transport, 
Testing, and Submission for Patients with Suspected 
Infection with Ebola Virus Disease
Background
CDC is working with the World Health Organization (WHO), the ministries of health, and other 
international organizations in response to an outbreak of EVD in West Africa, which was first 
reported in late March 2014. This is the largest outbreak of Ebola virus disease (EVD) ever 
documented and the first recorded in West Africa. For the latest information on the outbreak, 
see the 2014 Ebola Outbreak in West Africa (/vhf/ebola/outbreaks/guinea/index.html)
highlights.
EVD is one of numerous viral hemorrhagic fevers (VHF). It is a severe, often fatal disease in 
human and nonhuman primates. EVD is spread by direct contact with the blood or secretions 
(urine, feces, semen, breast milk, and possibly others) of an infected person or exposure to 
objects that have been contaminated with infected secretions. The incubation period is usually 8
–10 days (rarely ranging from 2 to 21 days). Patients can transmit the virus while febrile and 
through later stages of disease, as well as postmortem.
U.S. hospitals can safely manage a patient with EVD by following recommended isolation and 
infection control procedures (/vhf/ebola/hcp/infection-prevention-and-control-
recommendations.html). Standard, contact, and droplet precautions are recommended for 
management of hospitalized patients with known or suspected (/vhf/ebola/hcp/case-
definition.html) EVD.
Potentially infectious diagnostic specimens are routinely handled and tested in U.S. laboratories 
in a safe manner, through adherence to standard safety precautions as outlined below.
Purpose
(/vhf/ebola/pdf/ebola-lab-guidance.pdf)
Printable factsheet: Interim Guidance for Specimen Collection, Transport, Testing, and 
Submission for Patients with Suspected Infection with Ebola Virus Disease [PDF - 1 page]
(/vhf/ebola/pdf/ebola-lab-guidance.pdf)
This document provides interim guidance for laboratorians and other healthcare personnel 
collecting or handling specimens in the United States on appropriate specimen collection, 
transport and testing of specimens from patients who are suspected to be infected with Ebola 
virus.
Infection Control for Collecting and Handling Specimens
It is expected that all laboratorians and other healthcare personnel collecting or handling 
specimens follow established standards compliant with the OSHA bloodborne pathogens 
standard (https://www.osha.gov/pls/oshaweb/owadisp.show_document?
p_id=10051&p_table=STANDARDS), which encompasses blood and other potentially 
infectious materials. This includes wearing appropriate personal protective equipment 
(PPE) and adhering to engineered safeguards, for all specimens regardless of whether 
they are identified as being infectious.
Recommendations for specimen collection: full face shield or goggles, masks to cover all of 
nose and mouth, gloves, fluid resistant or impermeable gowns. Additional PPE may be 
required in certain situations.
Recommendations for laboratory testing: full face shield or goggles, masks to cover all of 
nose and mouth, gloves, fluid resistant or impermeable gowns AND use of a certified class II 
Biosafety cabinet or plexiglass splash guard, as well as manufacturer-installed safety 
features for instruments.
Specimen Handling for Routine Laboratory Testing (not for Ebola 
Diagnosis)
Routine laboratory testing includes traditional chemistry, hematology, and other laboratory 
testing used to support and treat patients. Precautions as described above offer appropriate 
protection for healthcare personnel performing laboratory testing on specimens from patients 
with suspected infection with Ebola virus. These precautions include both manufacturer installed 
safety features for instruments and the environment as well as PPE specified in the box above.
When used according to the manufacturer’s instructions, Environmental Protection Agency 
(EPA)-registered disinfectants routinely used to decontaminate the laboratory environment 
(benchtops and surfaces) and the laboratory instrumentation are sufficient to inactivate 
enveloped viruses, such as influenza, hepatitis C, and Ebola viruses.
When Specimens Should Be Collected for Ebola Testing
Ebola virus is detected in blood only after onset of symptoms, most notably fever. It may take up 
to 3 days post-onset of symptoms for the virus to reach detectable levels. Virus is generally 
detectable by real-time RT-PCR from 3-10 days post-onset of symptoms, but has been detected 
for several months in certain secretions. Specimens ideally should be taken when a symptomatic 
patient reports to a healthcare facility and is suspected of having an EVD exposure; however, if 
the onset of symptoms is <3 days, a subsequent specimen will be required to completely rule-out 
EVD.
Preferred Specimens for Ebola Testing
A minimum volume of 4mL whole blood preserved with EDTA, clot activator, sodium polyanethol 
sulfonate (SPS), or citrate in plastic collection tubes can be submitted for EVD testing. Do not 
submit specimens to CDC in glass containers. Do not submit specimens preserved in heparin 
tubes. Specimens should be stored at 4°C or frozen. Specimens other than blood may be 
submitted upon consult with the CDC by calling the Emergency Operations Center at 770-488-
7100.
Standard labeling should be applied for each specimen. The requested test only needs to be 
identified on the requisition and CDC specimen submission forms.
Storing Clinical Specimens for Ebola
Specimens should be stored at 4°C or frozen.
Diagnostic Testing for Ebola Performed at CDC
Several diagnostic tests are available for detection of EVD. Acute infections will be confirmed 
using a real-time RT-PCR assay (CDC test directory code CDC -10309 Ebola Identification) in a 
CLIA-accredited laboratory. Virus isolation may also be attempted. Serologic testing for IgM and 
IgG antibodies will be completed for certain specimens and to monitor the immune response in 
confirmed EVD patients (#CDC-10310 Ebola Serology).
Lassa fever is also endemic in certain areas of West Africa and may show symptoms similar to 
early EVD. Diagnostic tests including but not limited to RT-PCR, antigen detection, and IgM 
serology may be utilized to rule out Lassa fever in EVD-negative patients.
Transporting Specimens within the Hospital / Institution
In compliance with 29 CFR 1910.1030, specimens should be placed in a durable, leak-proof 
secondary container for transport within a facility. To reduce the risk of breakage or leaks, do not 
use any pneumatic tube system for transporting suspected EVD specimens.
Packaging and Shipping Clinical Specimens to CDC
(/vhf/ebola/hcp/packaging-diagram.html)
PACKAGING DIAGRAM (/VHF/EBOLA/HCP/PACKAGING-DIAGRAM.HTML)
Specimens collected for EVD testing should be packaged and shipped without attempting to 
open collection tubes or aliquot specimens. Specimens for shipment should be packaged 
following the basic triple packaging system which consists of a primary receptacle (a sealable 
specimen bag) wrapped with absorbent material, secondary receptacle (watertight, leak-proof), 
and an outer shipping package. See diagram » (/vhf/ebola/hcp/packaging-diagram.html)
The following steps outline the submission process to CDC.
• Hospitals should follow their state and/or local health department procedures for 
notification and consultation for Ebola testing requests and prior to contacting CDC.
• NO specimens will be accepted without prior consultation. For consultation call the EOC at 
770-488-7100.
• Contact your state and/or local health department and CDC to determine the proper 
category for shipment based on clinical history and risk assessment by CDC. State guidelines 
may differ and state or local health departments should be consulted prior to shipping.
• Email tracking number to EOCEVENT246@CDC.GOV
(mailto:EOCEVENT246@CDC.GOV).
• Do not ship for weekend delivery unless instructed by CDC.
• Ship to:
Centers for Disease Control and Prevention
ATTN STAT LAB: VSPB, UNIT #70
1600 Clifton Road NE
Atlanta, GA 30333
Phone 770-488-7100
• Include the following information: your name, the patient's name, test(s) requested, date of 
collection, laboratory or accession number, and the type of specimen being shipped.
• Include the CDC Infectious Disease (CDC Form 50.34
(http://www.cdc.gov/laboratory/specimen-submission/form.html)) and Viral Special 
Pathogens Branch [PDF - 2 pages] (/ncezid/dhcpp/vspb/pdf/specimen-submission.pdf)
specimen submission forms.
• On the outside of the box, specify how the specimen should be stored: refrigerated or 
frozen.
Occupational Health
Potential exposures to blood, body fluids and other infectious materials must be reported 
immediately according to your institution’s policy and procedures.
When to Contact CDC
CDC highly recommends contacting your state and/or local health department prior to 
contacting CDC.
CDC is available for consultation 24/7 at 770-488-7100.
CDC will continue to evaluate new information as it becomes available and will update this 
guidance as needed.
Additional Resources and Information
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I. PURPOSE 
 
This protocol describes the procedure for inactivation of filoviruses, arenaviruses, 
bunyaviruses, and paramyxoviruses; and the subsequent RNA extraction 
procedure. The inactivation procedure removes infectivity to ensure the safety of 
laboratory personnel handling the samples, while preserving virus genome. The 
RNA Extraction procedure isolates purified RNA from the inactivated biological 
matrices (samples) for subsequent genomic analyses such as RT-PCR 
diagnostics and genome sequencing. 
 
Samples appropriate for testing include whole blood, sera, and plasma from 
humans or animals. 
 





For RNA extraction, the sample is first lysed under highly denaturing conditions 
to remove infectivity and inactivate RNases, while ensuring isolation of intact viral 
RNA.  Sample inactivation is accomplished through use of a one-step sample 
homogenization/lysis procedure, in which the TriPure Isolation Reagent disrupts 
cells and denatures endogenous nucleases. After chloroform is added to 
the extract, the mixture is centrifuged and separates into three phases: a 
colorless aqueous (upper) phase, a white interphase and a red organic (lower) 
phase. The phases may then be separated and RNA recovered from the 
colorless aqueous phase, and DNA or protein from the interphase and red 
organic phase. 
 
Note: Published studies and in-house CDC/VSPB testing have documented the 
inactivation of enveloped RNA viruses by Tripure.   
 
Buffering conditions are then adjusted to provide optimum binding of the RNA to 
the Qiagen spin column.  The RNA binds to the column membrane, and 
contaminants are efficiently washed away in two steps using two different wash 
buffers.  High-quality RNA is eluted in a special RNase-free buffer, ready for 
direct use or safe storage.  The purified RNA is free of protein, nucleases, and 





A. Staff Responsibilities 
 
Position Responsibility 
Biosafety Officer -Reviews this SOP and performs a risk assessment for 
the work areas intended to conduct it; 
-Reviews and approves designated locations for sample 
preparation, storage and testing activities for the site 
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where each is to take place; 
Ensures staff is adequately trained in biosafety 
procedures.   
Quality Officer -Understands and enforces relevant certification 
information (agency or country-specific) as applicable to 
execution of this SOP.   
-Monitors adherence to this SOP by the personnel 
conducting it and oversees occurrence management 
where necessary.   
Laboratory Manager -  Ensures appropriate inactivation and extraction 
protocols have been used and documented; 
- Ensures retention of applicable logs and worksheets; 
- Ensures testing personnel have the appropriate training. 
Testing Personnel - Adheres to all SOP instructions and biosafety 
requirements; 
- Documents completion of sample inactivation and other 




B. Specific Safety and Containment Requirements and Responsibilities 
 
This section specifies actions and considerations to be taken into account 
according to the risk assessment conducted by the Biosafety Officer, such as 
known hazards specific to this SOP, and biosafety practices required for the safe 
execution of its procedures and use of reagents.  Adherence to appropriate 
safety guidelines and related biosafety SOPs is mandatory.  
 
WARNING: YOU MUST INACTIVATE VIRUS USING THE RECOMMENDED 
TRIPURE OR TRIZOL REAGENTS.   
 
DO NOT SKIP THIS CRITICAL INACTIVATION STEP. 
 
 
Note-- the following guidelines are excerpted from the World Health Organization’s 
publication: Interim Infection Prevention and Control Guidance for Care of Patients 
with Suspected or Confirmed Filovirus Haemorrhagic Fever in Health-Care 
Settings, with Focus on Ebola, and from the WHO Biosafety Manual. 
 
• Laboratory personnel should wear appropriate personal protective equipment 
(PPE), to include:  
o Closed shoes (no sandals) with disposable shoe covers, or laboratory 
boots.  
o Disposable gloves. Consider double gloving when the quality of gloves 
appears to be poor (e.g., if holes and tears form rapidly during use.  
o A disposable, impermeable gown with full-length sleeves. Front-buttoned 
standard laboratory coats are unsuitable, as are sleeves that do not fully 
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cover the forearms; use of disposable sleeves with standard lab coats do 
not proved a sufficient barrier. 
o Medical mask and eye protection (eye visor, or goggles, or face shield).  
o When aliquoting or undertaking any other procedure that may generate 
aerosols in the absence of other physical barriers such as a biosafety 
cabinet, particulate respirators (e.g., FFP2, or EN certified equivalent, or 
US NIOSH-certified N95), or powered air purifying respirators (PAPR) 
should be used.  
• Laboratory protective clothing must not be worn outside the laboratory, and it 
must be decontaminated before disposal. The removal of street clothing and 
change into dedicated laboratory clothing in addition to the use of disposable 
outer wear may be warranted based on institutional practice. 
• Dispose of pipette tips and other sharp objects in appropriate, puncture-resistant 
containers with disinfectant. 
o Ensure that puncture-resistant containers for sharps objects are placed 
as close as possible to the immediate area where the objects are being 
used (‘point of use’) to limit the distance between use and disposal, and 
ensure the containers remain upright at all times. Ensure that the 
puncture-resistant containers are securely sealed with a lid and replaced 
when 3/4 full. 
• When removing PPE, avoid any contact between the soiled items (e.g. gloves, 
gowns) and any area of the face (i.e. eyes, nose or mouth). 
• Do not hang up the apron or gown for reuse- discard immediately. 
• Perform hand hygiene immediately after the removal of PPE used during 
specimen handling and after any contact with potentially contaminated surfaces 
even when PPE is worn. 
• Place specimens in clearly-labelled, non-glass, leak-proof containers and deliver 
directly to designated specimen handling areas. 
• Disinfect all external surfaces of specimen containers thoroughly (using an 
effective disinfectant) prior to transport. The Ebola virus can be eliminated with 
denaturing detergents and sodium hypochlorite (bleach) or calcium hypochlorite 
(bleaching powder) at appropriate concentrations. (See Attachment D for further 
instructions). 
• For Waste Management: 
o Wear heavy duty/rubber gloves, impermeable gown, closed shoes (e.g. 
boots) and facial protection (mask and goggle or face shield), when 
handling infectious waste (e.g. solid waste or any secretion or excretion 
with visible blood, even if it originated from a normally sterile body cavity).  
o Goggles with medical mask provide greater protection than visors with 
medical mask, from splashes that may come from below when pouring 
liquid waste from a bucket. Avoid splashing when disposing of liquid 
infectious waste. 
o Waste should be segregated at point of generation to enable appropriate 
and safe handling. 
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o Sharp objects (e.g. needles, syringes, glass articles) and tubing that has 
been in contact with blood or body fluids should be placed inside puncture 
resistant waste containers. These should be located as close as practical 
to the area where the items are used. 
o Collect all solid, non-sharp, infectious waste using leak-proof waste bags 
and covered bins. Bins should never be carried against the body (e.g. on 
the shoulder). 
o A fire pit or incinerator may be used for short periods during an outbreak 
to destroy solid waste. However, it is essential to ensure that total 
incineration has taken place. Caution is also required when handling 
flammable material and when wearing gloves due to the risk of burn 
injuries if gloves are ignited. 
o Autoclaved or incinerated waste should be placed in a designated pit of 
appropriate depth (e.g. 2 m or about 7 feet) and filled to a depth of 1–1.5 
m (or about 3–5 feet). After each waste load, the waste should be covered 
with a layer of soil 10 –15 cm deep. 
o The area designated for the final treatment and disposal of waste should 
have controlled access to prevent entry by animals, untrained personnel or 
children. 
• In case of exposure: 
o Persons with percutaneous or muco-cutaneous exposure to blood, body 
fluids, secretions, or excretions from a patient with suspected or confirmed 
Hemorrhagic Fever (HF) should immediately and safely stop any current 
tasks, and safely remove PPE. Remove PPE carefully because exposure 
during PPE removal can be just as dangerous for nosocomial transmission 
of HF.  
o Immediately wash the affected skin surfaces or the percutaneous injury 
site with soap and water. Accordingly, irrigate mucous membranes (e.g. 
conjunctiva) with copious amounts of water or an eyewash solution. 
o Immediately report the incident to Supervisor. Exposed persons should 
be medically evaluated, including for other potential exposures (e.g., HIV, 
HCV) and receive follow-up care, including fever monitoring, twice daily for 
21 days after the incident. 
o Immediate consultation with an expert in infectious diseases is 




• Some of the reagents used to purify RNA are caustic.  Read the MSDS sheets 
and be familiar with treatment protocols in case of accidental exposure and how 
to clean up any spills. 
• TriPure Isolation Reagent contains phenol, which is highly caustic to skin. 
• Do not mix TriPure Isolation Reagent with bleach.  TriPure Isolation Reagent 
contains guanidine thiocyanate.   Guanidine salts can form highly reactive 
compounds when combined with bleach.  
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o If liquid containing these buffers is spilled, clean with suitable laboratory 
detergent and water.  
o If the spilled liquid contains potentially infectious agents, clean the 
affected area first with laboratory detergent and water, and then with 1% 




IV. SAMPLE HANDLING 
 
Samples appropriate for testing include whole blood, sera, and plasma from 
humans or animals.  
Samples must be thoroughly evaluated to determine the proper initial processing 
area and handling procedures to be used.  This should take into account the 
patient’s clinical history, clinical signs, exposure risks, geographic area of origin, 
and any accompanying communications from the submitting physician or 
diagnostic laboratory.  
 
For additional sample handling biosafety guidance, refer to:   
World Health Organization. Interim Infection Prevention and Control 
Guidance for Care of Patients with Suspected or Confirmed Filovirus 
Haemorrhagic Fever in Health-Care Settings, with Focus on Ebola; 





V. REAGENTS - MATERIALS/SUPPLIES – EQUIPMENT 
 




• Standard hospital detergent  
• Disinfectant (minimum of 0.5% sodium hypochlorite – see Attachment D)* 
Note: 70% ethanol or methanol are not appropriate as disinfectants 
Supplies 
• Disposable single-use gloves 
• Disposable, impermeable gown  
• Disposable shoe covers or laboratory boots 
• Disposable mask 
• Eye protection or face shields to protect eyes, nose, mouth 
• Additional PPE as needed, based on risk assessment 
• Biohazard waste bags/container 
• Sharps container 
• Disinfectant container 
• Absorbent towels 
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Equipment 
• Plexiglass shield or splashguards, at minimum  
• Class II Biosafety Cabinet, if available 
 
*Note-- Chlorine solutions gradually lose strength, thus fresh solutions must 
be prepared daily. 
 
See Appendix D for instructions on how to prepare disinfectant (1 part 3.5% sodium 
hypochlorite + 6 parts water = 0.5% sodium hypochlorite solution) 
 
B. Materials/Supplies/Equipment for Procedure 
 
Molecular biology-grade reagents should be used and plastics should be sterile and 
certified RNAse/DNAse free. 




• Tripure Reagent (Roche Catalog # 11667157001), or Trizol (Invitrogen 
Catalog # 15596) 
• Qiagen RNeasy kit (Catalog # 74104), 
• Molecular grade sterile distilled water (RNAse and DNAse free) 
• Chloroform (isoamyl alcohol free – i.e., Sigma catalog #C2432 or equivalent 
 
Supplies 
• Screw cap microcentrifuge tubes  
• Pipette tips 
• Laboratory marking pen  
• Ice bucket containing ice for reaction or isolation tubes  
• 20µl, 200µl, and 1000µl adjustable pipettes and aerosol barrier tips  









C. Reagent Preparation 
 
1. Buffer RPE is supplied as a concentrate. Before using for the first time, add 4 
volumes of ethanol (96–100%) as indicated on the bottle to obtain a working 
solution 
2. Buffer RLT may form a precipitate upon storage. If necessary, re-dissolve by 
warming, and then place at room temperature (20–25°C). 
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An established quality assurance (QA) program should be in place in order to 
minimize the risk of errors and to maximize the possibility of discovering errors if 
they occur.  The institutional QA program must follow the recommendations from 
established standards organizations for quality assurance. 
 
Prior to instituting this protocol, dedicated laboratory space which is physically 
segregated should be designated for each of the following activities and a risk 
assessment done of the work environment and processes.  These include 
designated space for: 
• Specimen receiving, accession, and storage; 
• Sample inactivation and nucleic acid extraction; 
• Master mix preparation (clean space); 
• Reaction mixture and sample addition; 
• Amplification and detection. 
 
To avoid sample contamination:  
• Always wear powder-free gloves when handling reagents. 
• Never return an aliquot to the original container. 
• Maintain separate areas for assay setup.  
• Maintain separate areas for handling of nucleic acids.  
• Maintain separate, dedicated equipment (e.g., pipettes, microcentrifuges) 
and supplies (e.g., screw cap microcentrifuge tubes, pipette tips) for 
assay setup and handling of extracted nucleic acids.  
• Wear a clean lab coat and powder-free disposable gloves (not previously 
worn) when setting up assays.  
• Change gloves between samples whenever you suspect they may be 
contaminated.  
• Keep reagent and reaction tubes capped or covered as much as possible.  
 
General Equipment preparation:  
• Work surfaces, pipettes, and centrifuges should be cleaned and 
decontaminated with cleaning products such as 10% bleach or “RNase 
Zap™” or equivalent, to minimize risk of nucleic acid contamination. 
 
At each step, verify that the integrity of all sample information is maintained. If 
clerical errors are discovered, correct and document by initialing. If the integrity of 
sample identity is compromised at any step, processing must be repeated for the 
affected steps of the analysis. Document the actions taken. Specimen identity 
must be documented and verified at every step as part of standard operating 
procedure. 
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Record the lot/batch number of reagents and their expiration dates in applicable 




Generally, total RNA will be isolated from samples.  However, in any case where 
RNA selection occurs (e.g. isolation of cytoplasmic RNA only), total RNA must be 
isolated concurrently from negative control samples for use as template in 
subsequent control reactions (i.e. ß2-microglobulin control PCR).   
 
It is recommended to run an internal extraction control such as RNase P or Beta 
2 microglobulin (B2M), for every patient sample tested. Additionally, one 
Negative Extraction Control and one Negative PCR Control should be conducted 
in each run. 
 
If controls do not perform as expected during PCR assay, the entire assay should 
be repeated, including extraction phase.  A discordant control result may indicate 






A. Procedure for Inactivation 
 
WARNING: YOU MUST INACTIVATE VIRUS USING THE RECOMMENDED 
TRIPURE OR TRIZOL REAGENTS.   
 
DO NOT SKIP THIS CRITICAL INACTIVATION STEP. 
 
Note —before performing the following steps, a facility-based risk assessment 
must first be conducted, then the work done in accordance with WHO guidance. 
All laboratory sample processing must take place under a Class II biosafety 
cabinet, or higher. Do not carry out procedure on the open bench.   
 
Preparation of Equipment and Laboratory Work Area 
1. Use appropriate personal protective equipment (PPE), according to risk 
assessment and as recommended in the Safety section of this SOP.  
 
2. Prepare disinfectant (minimum of 0.5% sodium hypochlorite or other 
laboratory grade denaturing disinfectant) and add 100 ml of disinfectant to the 
disinfectant container. 
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1. Dilute sample 1:10 with Tripure or Trizol reagent (generally 50 µl of sample to 
500 µl Tripure; or 100 µl sample to 1000 µl (1ml) Tripure) in clean screw cap 
microcentrifuge tube.  
2. Mix well by inverting tube 10 times.  To avoid aerosols, do not vortex or shake 
tube. 
3. Incubate sample for at least 10 minutes at room temperature (20-25°C). 
4. Transfer to a clean tube, then invert tube 10 times to inactivate the interior of 
the tube. 
5. Clean the surface of the tube by dunking into a container of disinfectant, then 
wipe and put tube into a second leak-proof container before removing from the 
biosafety cabinet for transport or storing, as noted. 
 
Notes:   
• At this stage, samples are inactivated (non-infectious) and standard 
precautions for maintaining nucleic acids and minimizing cross-
contamination should be followed. 
• Samples can be stored for later RNA extraction procedure.   
o Samples should be stored at 2 to 8°C for up to 6 hours. 
o Samples held from 6 hours to 2 weeks should be stored at -20°C.   
o Samples held for longer than 2 weeks should be stored at -80°C.   
o Frozen samples must not be thawed more than once.  Repeated 
freezing and thawing leads to denaturation and precipitation of 
proteins, causing reduced yields of the isolated viral RNA. 
• Circumventing the Tripure step and doing just the RNeasy is dangerous 




B. Procedural steps for RNA Extraction (see Attachment F for procedure 
checklist) 
WARNING: DO NOT CONTINUE UNLESS YOU HAVE INACTIVATED THE VIRUS 
USING THE RECOMMENDED TRIPURE OR TRIZOL REAGENTS DESCRIBED 
ABOVE.   
 




• Perform all centrifugation steps at room temperature (20–25°C) in a standard 
microcentrifuge.  
• Work surfaces, pipettes, and centrifuges should be cleaned and 
decontaminated with cleaning products such as 10% bleach or “RNase 
Zap™” or equivalent, to minimize risk of nucleic acid contamination. 
 
1. Place inactivated samples in an appropriately ventilated workspace.  This 
should be a designated space within the lab for sample manipulation.  Allow 
frozen samples to thaw. 
2. To the sample, add 200µL chloroform.  
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3. Vortex, then let sit for 5-15minutes (on ice, if possible), with frequent vortexing 
or vigorous shaking. 
4. Centrifuge tube at 14,000 rpm for 15 minutes. 
5. The mixture will separate into three phases: 
a. Colorless aqueous (upper) phase (RNA) 
b. White interphase (protein) 
c. Red organic (lower) phase (DNA) 
Note: For illustration, see Attachment E. 
 
6. Remove the top (colorless) layer with a micropipettor and place in a new tube. 
(Note:  Do not disturb white (protein) layer, as inclusion of protein will 
prevent further extraction of total RNA.) 
-------------------------------------------------------------------------------------------------- 
7. Add 1 volume of 70% ethanol  
Generally, 1 volume = the volume of Tripure Isolation Reagent (500µl per 
100µl sample). 
8. Mix well – DO NOT Centrifuge. 
9. Add 700µl of the mixture to the RNEasy spin column. Include any precipitate 
that may have formed. 
10. Spin at >10,000rpm for 15 seconds. 
11. Discard flow-through. Wipe off drips with clean paper towel. 
12. Concentrate the RNA by applying multiple aliquots of the same sample to a 
single column and repeating steps 9-11. 
13. Add 700µl RW1 buffer. 
14. Spin 15 seconds at room temperature. 
15. Discard flow-through. Wipe off drips with clean paper towel. 
16. Add 500µl RPE. 
17. Spin 15 seconds. 
18. Discard flow-through. Wipe off drips with clean paper towel. 
19. Add 500µl RPE. 
20. Spin 2 minutes. 
21. Discard collection tube. 
22. Put column in new collection tube and spin 1 minute. 
23. Put column in a sterile, nuclease-free 1.5ml microcentrifuge tube for elution of 
RNA. 
24. Add 50µl RNAse-free water to the column membrane. 
Note:  Let sit at room temperature (20–25°C) for 1 minute to maximize elution. 
25. Spin 1minute at room temperature. Purified RNA is found in the eluent which 
should be stored at -20°C to -80°C until tested. 
 
The sample is now ready for molecular testing.  (See SOP# VSPB1101: Ebola virus 
(Zaire) nucleoprotein Real Time Reverse Transcription Polymerase Chain Reaction 
(Real Time RT-PCR) 
 
 
C. Clean up 
 
1. Clean and decontaminate materials, equipment, and workspace. It is 
recommended to first clean with standard hospital detergent, followed by 
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decontamination with chlorine bleach, as organic matter can inactivate 
disinfectants. 
2. Dispose of materials in biohazard waste bag or sharps container, in 
accordance with biosafety policies and the precautions described in Safety 
section of this SOP.   
 
 
V. LIMITATIONS OF PROCEDURE 
 
A minimum of 1:5 dilution (e.g. 200µl of serum placed into 1000µl of Tripure 
Isolation reagent or Trizol for a total of 1ml) with a GITC-containing buffer (e.g. 
Tripure Isolation Reagent) must be used to ensure complete inactivation of viral 
particles before removal from the containment laboratory.  
 
It is important to pay close attention to technique and follow recommended 





Record keeping is essential for good laboratory practice.  Laboratory personnel 
are responsible for documenting completion of applicable sample inactivation 
and extraction procedural steps in appropriate logs and worksheets.  See 
Attachments for examples of inactivation protocol check list and example 
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Attachment A: Checklist: Inactivation by Tripure/Trizol Lysis Buffers – Non-
Tissues 
 
Attachment B: Example Worksheet for Sample Inactivation 
 
Attachment C: Checklist Using Qiagen’s RNeasy Kit 
 
Attachment D: How to Make Chlorine Solutions for Environmental Disinfection  
 
Attachment E: Illustration of Separation Phases during Step # 5 of RNA 
Extraction Procedure 
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Checklist: Inactivation by “Tripure/Trizol” Lysis Buffers – Non-Tissues (ex., blood, 
serum) 
 
Date:_______________________  Location of work:___________________ 
 
Laboratorian (print name):_________________________Email: ___________________ 
Patient Diagnosis (INFO):_________________________________________  
Tests Requested__________________________________ 
# of Specimens Inactivated:______ 
 
 Procedure             Initial: 
  Add 0.5mL to 1.0mL of undiluted lysis reagent (Tripure or Trizol reagent) to clean 
microcentrifuge tubes 
 
  Dilute specimen(s) in at least 10 volumes of lysis buffer (Tripure or Trizol) reagent 
(10:1 ratio).  For example:  
• 50uL of specimen + 500uL of lysis reagent  
• 100uL of specimen + 1000uL of lysis reagent 
 
  Mix well by vortexing, or invert tube 10 times 
 
  Incubate specimen in lysis buffer for at least 10 minutes at room temperature 
 
  Transfer contents to clean tube 
  Vortex (or invert tube 10 times) to mix and to inactivate interior of tube 
 
  Clean the surface of the tube by dunking into a container of disinfectant, then wipe 
and put tube into a second leak-proof transfer container before removing from the 
biosafety cabinet for testing. 
------------------------------------------------------------------------------------------------------------ 
 
  I certify that I have been trained to complete the above inactivation protocol, and will 
report to my supervisor if any further training or clarifications are needed to competently 
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Attachment C: Checklist Using Qiagen’s RNeasy Kit  
RNA EXTRACTION 
WARNING: YOU MUST FIRST INACTIVATE VIRUS USING THE 
RECOMMENDED TRIPURE OR TRIZOL REAGENTS.   
 
DO NOT SKIP THIS CRITICAL INACTIVATION STEP. 
Adaptation of Qiagen’s RNeasy kit for use with Tripure reagent 
Using Qiagen’s RNeasy kit: 
 
  Add sample to Tripure for a 1:10 dilution (i.e, 100uL blood to 1000uL 
Tripure) 
  Incubate 10 minutes at room temperature, transfer to new tube, disinfect 
the outside of tube 
 
  Can freeze for later extraction (Do not keep at 4ºC for more than 6 hours) 
 
  Add 200uL of Chloroform 
  
  Vortex, incubate on ice if possible 5-15 minutes with frequent vortexing 
 
  Spin 14,000 RPM, 15 minutes 
 
  Pull off top layer being careful not to disturb middle (protein) layer and 
place in new tube 
 
 Add 1 volume of 70% ethanol to the top layer, mix well 
 
 Add 700uL to spin column, spin >10,000rpm for 15 seconds, discard flow-
through (can repeat several times to concentrate the RNA) 
 
  Add 700uL RW1 buffer, spin 15 seconds, discard flow-through 
 
  Add 500uL RPE, spin 15 seconds, discard flow-through 
 
  Add 500uL RPE, spin 2 minutes, discard collection tube 
 
  Put column in new collection tube and spin 1 minute 
 
  Put column in a new collection tube, add 30-50uL RNAse free water, 
incubate 1 minute  
 
  Spin 1 minute (do not use the eluate again to try to get more RNA – you 
will lose RNA)  
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Attachment D: How to Make Chlorine Solutions for Environmental Disinfection 
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I. PURPOSE 
 
The Ebola virus (Zaire) nucleoprotein Real Time RT-PCR Protocol includes a 
primer and dual-labeled hydrolysis (Taqman®) probe set to be used in real-time 
PCR assays for the in vitro qualitative detection of viral RNA isolated from human 





Real-time polymerase chain reaction, also called quantitative real-time 
polymerase chain reaction (Q-PCR) is a laboratory technique based on the 
polymerase chain reaction (PCR), which is used to monitor the PCR amplification 
products in real time.  A variation of Q-PCR is reverse transcription Q-PCR (Q-
RT-PCR) which includes a reverse transcription step to create a complementary 
DNA strand from each single stranded RNA genome.  In Q-PCR, the specific 
amplification product is detected via the release of fluorescent dyes during each 
amplification cycle.  The fluorescent dyes are usually linked to oligonucleotides 
(called probes), which bind specifically to the amplified product.  Monitoring the 
fluorescence intensities during the Q-PCR allows the detection and quantitation 
of the accumulating of product without having to open the reaction tubes after the 




A. Staff Responsibilities 
 
Position Responsibility 
Biosafety Officer -Reviews this SOP and performs a risk assessment for 
the work areas intended to conduct it; 
-Reviews and approves designated locations for sample 
preparation, storage and testing activities for the site 
where each is to take place; 
Ensures staff is adequately trained in biosafety 
procedures.   
Quality Officer -Understands and enforces relevant certification 
information (agency or country-specific) as applicable to 
execution of this SOP.   
-Monitors adherence to this SOP by the personnel 
conducting it and oversees occurrence management 
where necessary.   
Laboratory Manager -  Ensures appropriate protocols have been used and 
documented; 
- Ensures retention of applicable logs and worksheets; 
- Ensures testing personnel have the appropriate training. 
Testing Personnel - Adheres to all SOP instructions and biosafety 
requirements; 
- Documents completion of all procedural steps, as 
applicable. 
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B. Specific Safety and Containment Requirements and Responsibilities 
 
This section specifies actions and considerations to be taken into account 
according to the risk assessment conducted by the Biosafety Officer, such as 
known hazards specific to this SOP, and biosafety level and practices required for 
the safe execution of its procedures and use of reagents.  Adherence to 
appropriate level safety guidelines and related biosafety SOPs is mandatory.  
 
 
IV. SAMPLE HANDLING 
Samples addressed by this protocol include RNA extracted from the following 
human or animal samples: whole blood, sera, or plasma).  
 
For information regarding extraction procedures, see VSPB-1100: Inactivation of 
Enveloped RNA Viruses and Extraction of Genomic Material (RNA) using Tripure 
or Trizol Reagents and the Qiagen RNeasy Kit. 
 
 
V. REAGENTS - MATERIALS/SUPPLIES – EQUIPMENT 
 




• Standard hospital detergent 
• Disinfectant (minimum of 0.5% sodium hypochlorite)* 
Supplies 
• Disposable, powder-free gloves 
• Laboratory coat 
• Additional PPE as needed, based on risk assessment 
• Biohazard waste bags/container 
• Sharps container 
• Disinfectant container 
• Absorbent towels 
Equipment 
• Class II Biosafety Cabinet, if available 
• Plexiglass shield or splashguards, at minimum 
 
*Note-- Chlorine solutions gradually lose strength, thus fresh solutions must 
be prepared daily. 
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B. Materials/Supplies/Equipment for Procedure 
 
Molecular biology-grade reagents should be used and plastics should be sterile 
and certified RNAse/DNAse free. 
 





• Invitrogen’s Superscript III Platinum®  One Step qRT-PCR Kit (cat # 11732-
020): 
o 2X PCR Master mix 
o RT/Platinum Taq Mix 
o Rox dye 
• Molecular grade sterile nuclease free distilled water (RNase and DNase free) 
(Promega part no. P119C) 
• RNaseOUTTM Recombinant Ribonuclease Inhibitor (Invitrogen cat # 10777-
019)    
• Forward primer: (50µM) ZaiNPTaqM1-F  
• Reverse primer: (50µM) ZaiNPTaqM1-R   
• Probe: (5µM) ZaiNPTaqMProbe 1  
o TaqMan® probes are labeled at the 5’-end with the reporter molecule 
(6-carboxyfluorescein [FAM] and with the quencher, Blackhole 
Quencher 1 [BHQ1]  Biosearch Technologies, Inc., Novato, CA) at the 
3’-end. 
• Positive Control RNA isolated from primary or transformed cell culture 
supernatants or lysates 
• Negative control RNA 
Supplies 
• Laboratory marking pen  
• Ice bucket containing ice for reaction or isolation tubes  
• 2µl, 10µl, 20µl, 200µl, and 1000µl adjustable pipettes and aerosol barrier tips  
• 0.2ml PCR reaction optical tube strips or plates (ABI part no. 4306737 or 
Eppendorf cat #’s 951010006 and/or 951020303) 
• Optical strip caps or optical sealing film (ABI part no. 4313663 or Eppendorf 
cat no. 951023035) 
• Sterile, nuclease free 2.0ml microcentrifuge tubes (ABI part no. 4305936) 
Equipment 
•  Microcentrifuge  
• 96-well plate compatible centrifuge 
• Vortex  
• Real-time PCR detection system such as the Applied Biosystems 7500 or 
7900HT Real-Time PCR System. 
• Applied Biosystems’ Sequence Detection Software ver. 1.3.1 or 7900HT ver. 
2.3 Sequence Detection Systems or similar software 
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C. Reagent Preparation 
1. Frozen test reagents must be thawed and mixed by pipetting or by brief 
vortexing for 15 seconds followed by centrifugation at 6000 x g (8000 rpm) for 
15 seconds; followed by placing the reagents in an ice bucket filled with ice to 
keep the labile components protected from excess temperatures.                                                                      
NOTE— Enzymes (i.e., Taq polymerase) are labile and should be kept frozen 
(-15 to -25 ºC) and not exposed to excessive freeze-thaw cycles.  To avoid 
freeze-thaw cycling of enzymes, they should be stored separately in a cold 
block at -15 to -25 ºC.  
2. For additional information on Primers and Probes, refer to Attachment A. 
3. Some core reagents may be provided in bulk quantities.  In such cases, these 
reagents need to be aliquotted before use to avoid excess freeze-thaw cycles 
in volumes appropriate to the laboratory workload.  Label all aliquots with the 
following information:  
a. Name of component 
b. Concentration 
c. Date aliquotted 
d. Expiration 
e. Initials of person who prepared the aliquot 
f. Volume of aliquot 








An established quality assurance (QA) program should be in place in order to 
minimize the risk of errors and to maximize the possibility of discovering errors if 
they occur.  The institutional QA program must follow the recommendations from 
established standards organizations for quality assurance. 
 
• Prior to instituting this protocol, dedicated laboratory space which is 
physically segregated should be designated for each of the following 
activities and a risk assessment done of the work environment and 
processes.  These include designated space for: 
o Specimen receiving, accession, and storage; 
o Sample inactivation and nucleic acid extraction; 
o Master mix preparation (clean space); 
o Reaction mixture and sample addition; 
o Amplification and detection. 
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• To avoid sample contamination:  
o Always wear powder-free gloves when handling reagents. 
o Never return an aliquot to the original container. 
o Maintain separate areas for assay setup.  
o Maintain separate areas for handling of nucleic acids.  
o Maintain separate, dedicated equipment (e.g., pipettes, 
microcentrifuges) and supplies (e.g., screw cap microcentrifuge tubes, 
pipette tips) for assay setup and handling of extracted nucleic acids.  
o Wear a clean lab coat and powder-free disposable gloves (not 
previously worn) when setting up assays.  
o Never wear the same glove/gown at multiple stations.  
o Change gloves between samples whenever you suspect they may be 
contaminated.  
o Keep reagent and reaction tubes capped or covered as much as 
possible.  
 
• General Equipment preparation:  
o Work surfaces, pipettes, and centrifuges should be cleaned and 
decontaminated with cleaning products such as 10% bleach or 
“RNase Zap™” or equivalent, to minimize risk of nucleic acid 
contamination. 
 
• At each step, verify that the integrity of all sample information is 
maintained. If clerical errors are discovered, correct and document by 
initialing. If the integrity of sample identity is compromised at any step, 
processing must be repeated for the affected steps of the analysis. 
Document the actions taken. Specimen identity must be documented and 
verified at every step as part of standard operating procedure. 
 
• Record the lot/batch number of reagents and their expiration dates in 
applicable PCR worksheets and logs (see example in the Attachment B).   
• All PCR reagents should be stored according to manufacturer 





• Quality control materials consist of: 
o Positive Control (RNA isolated from cell cultures infected with known 
virus) 
o Negative control  
o No template controls (NTC)) – Contains reaction mix (buffers, primers, 
probes) but no RNA.  
o Suitable housekeeping gene (e.g. 18S RNA) - should be included in 
conjunction with any sample extracted from a clinical specimen to 
ensure the quality of the RNA extraction procedure 
o Mock extraction controls (MOCK) - provides a secondary negative 
control that validates the nucleic extraction procedure, reagent 
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integrity, and non-reactivity of the sample matrix (cell culture, serum, 
etc.) 
 
• Control materials should be included in each run. 
 
• Reactions should be prepared so that the Negative Control is set up first, 
then unknown samples, followed by the Positive Control, and lastly, another 
Negative Control.  Preparation in this order will reveal whether poor technique 
may have resulted in positive samples contaminating the Negative Control 
and other unknown samples. 
 
• If controls do not perform as expected, the assay should be repeated.  A 
discordant control result may indicate a procedural error.  





A. Preparation of Equipment and Laboratory Work Area 
 
Notes:  
• All work tasks in the Molecular Laboratory are restricted to work zones 
which are based on the potential to spread contamination (see section on 
Quality Assurance). 
• The preparation of the Master Mix should be conducted within a PCR 
workstation.   
 
1. Use appropriate personal protective equipment (PPE), according to risk 
assessment and as recommended in the Safety section of this SOP.  
 
2. Prepare disinfectant (minimum of 0.5% sodium hypochlorite) and add 100 ml 
of disinfectant to the disinfectant container. 
 
3. Clean the work area where the tests will be performed with disinfectant. 
 
 
B. Reagent Set-up 
 
NOTE:  Keep all reagents on ice during assay set up. 
 
Primers and probes  
1. Thaw frozen aliquots of primer and probes.   
2. Vortex all primers and probes to ensure uniform mixing.  
3. Briefly centrifuge all primers and probes and then place on ice.  
 
 
RT-PCR reagents  
1. Thaw master mix on ice. 
2. After thawing, mix by inversion. 
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3. Briefly centrifuge master mix and enzyme, and then place back on ice.  
 
 
Reaction Assay Mixtures 
Reaction assay mixtures are made as a cocktail in a separate clean room and 
dispensed into the reaction wells. Water, extracted nucleic acid, or positive 
template controls are then added to the appropriate test reactions and controls.  
1. Label one 1.5 ml microcentrifuge tube for preparation of the master mix.  
2. Determine the number of reactions (N) to set up per assay. It is necessary to 
make excess reaction cocktail to allow for pipette carry over. See below:  
a. If number of samples (n) including controls = 1 to 14, then N = n + 1  
b. If number of samples (n) including controls > 15, then N = n + 2  
3. Master Mix: Calculate the amount of each reagent to be added for each 






2X PCR Master Mix  N x 25µl  N x 25µl 
RT/Platinum Taq Mix N x 1µl  N x 1µl 
Forward primer (50µM stock)  N x 1µl  N x 1µl 
Reverse primer (50µM stock) N x 1µl  N x 1µl 
Probe (5µM stock)  N x 1µl  N x 1µl 
*** ROX *** N x 0.1µl N x 1.0µl 
*** Nuclease free water *** N x 15.9 N x 15µl 
Total volume  N x 45.0µl  N x 45.0µl 
 
***ROX = use 0.1µl for reactions run on the ABI7500 or 1µl for the ABI7900, 




C. Procedural steps 
 
1. In the assay set up area: 
a. Dispense reagents in accordance with above table into labeled 1.5ml 
microcentrifuge tubes.  
b. After final addition of the water, mix reaction mixtures by pipetting up 
and down. Do not vortex. 
c. Centrifuge for 5 seconds to collect contents at bottom of the tube, and 
then place the tube on ice.  
d. Set up reaction strip tubes or plates in 96-well cooler rack or on ice.  
e. Dispense 45µl of each master mix into each well.  
f. Before moving the plate to the nucleic acid handling area, set up the 
no template control (NTC) reactions in the assay set-up area by 
pipetting 5µl of nuclease free water into the NTC wells.  
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g. Cover the reaction plate with optical adhesive cover and move the 
reaction plate to the nucleic acid handling area. 
h. Waste should be removed from the lab daily.  
 
 
2. In the nucleic acid handling area: 
 
a. Vortex the tubes containing the samples for 5 seconds.  
b. Centrifuge tubes for 5 seconds.  
c. Pipette 5µl of the sample into the appropriate well for that sample. 
Repeat for the remaining samples.  
d. Note: Change tips after each reagent addition, and cap the tubes at 
logical intervals or as soon as possible after sample RNA addition (e.g. 
end of a row). 
e. Add 5µl of mock extracted sample to the MOCK wells. Cap MOCK 
wells. 
f. Pipette 5µl of human positive control RNA into the appropriate wells. 
Cap wells.  
g. Label: 
If using 8-tube strips: 
1) Label the TAB of each strip to indicate sample position (DO NOT 
LABEL THE TOPS OF THE REACTION TUBES!).  
2) Briefly centrifuge tube strips for 10-15 seconds. Return strip tubes 
to cold rack/ice.  
If using plates: 
3) Label the edge of the plate such that the label does not cover any 
of the wells.   





The reaction volume is 50µl. 
 
 *Fluorescence data for test fluorochromes (FAM) and reference standard 
(ROX) should be collected during the 55°C incubation step. Use the detector 
program named ZEBOV-NPdx with the following condition:  
 
 Conditions  
Reverse transcription 50°C for 15 min  
Taq inhibitor inactivation  95°C for 2 min  
PCR amplification (40 cycles)  95°C for 15 sec  
55°C for 1 min*  
 
 
4. Post-Amplification:  
 
The expected product size is 79bp. 
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a. Open the diagnostic run file using suitable software (e.g. ABI’s 
Sequence Detection Software ver. 1.3.1). 
1) Go to the Results tab, and then the Amplification plot tab 
2) Click “Auto Ct” on the right hand side, and then click the Analyze 
button below. 
3) Export the results (under the File menu) and note the Threshold 
level that was set automatically during the analysis. 
 
 
A. Clean up 
 
Do Not Open Tubers or PCR Plates! 
 
1. Clean and decontaminate materials, equipment, and workspace. It is 
recommended to first clean with standard hospital detergent, followed by 
decontamination with chlorine bleach, as organic matter can inactivate 
disinfectants. 
2. Dispose of materials in biohazard waste bag or sharps container, in 
accordance with biosafety policies and the precautions described in Safety 
section of this SOP.   
 
 
V. INTERPRETATION OF RESULTS 
 
1. Evaluate controls for acceptability: 
a. All positive samples should exhibit amplification curves with Ct values 
that cross the threshold line at or before 40 cycles, thus indicating the 
presence of RNA and that the specimen is of acceptable quality.  
If the positive RNA control fails to exhibit CT values that cross the 
threshold at or before 40 cycles the assay is invalid and must be 
repeated. Failure to detect ZEBOV-NP in any of the positive samples 
may indicate:  
1) Improper extraction of nucleic acid from samples resulting in loss 
of RNA or carry-over of inhibitors from specimens. 
2) Absence of sufficient RNA to enable detection.  
3) RNA degradation due to poor specimen shipping conditions or 
handling procedures. 
4) Improper assay set up and execution.  
5) Reagent or equipment malfunction. 
 
b. The NTC reactions and mock extraction controls for probe/primer sets 
should not exhibit fluorescence curves that cross the threshold line 
before 40 cycles. If a false positive occurs with one or more of the 
primer and probe NTC reactions, sample contamination may have 
occurred. Invalidate the run and repeat the assay with stricter 
adherence to the procedure guidelines. 
 
2. Unknown Specimen Interpretation: 
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a. In order for a test run to be valid, all NTC reactions must be negative 
without an amplification curve. If one or more NTC fails, the entire run 
is invalid and potential sources of contamination should be identified 
and corrected. Re-test the purified specimen and controls, and re-
analyze.  Results should NOT be reported until all false-positive NTC 
reactions are corrected. 
b. The external negative processing control associated with each 
extraction batch should be negative with no amplification curves. If the 
external sample processing negative control for a set of extracted 
specimens is positive, all results for those specimens are invalid. Re-
test the purified specimen and controls and re-analyze. If the re-test for 
the processing control results is positive, then re-extract the specimens 
and controls. Results should NOT be reported until all false-positive 
negative processing control reactions are corrected. 
c. A specimen is considered positive for Ebola virus (Zaire) if the 
specimen has a positive amplification result using this assay, if the 
above conditions are met.  
d. A specimen is considered negative for Ebola virus (Zaire) if the assay 
does not have a positive amplification result and the internal reaction 
control (i.e., 18s rRNA or B2 Microglobin if whole blood) assay has a 
positive amplification result. If the specimen is serum, these internal 
controls may not be valid. Please contact the CDC via email at 
EOCEVENT246@CDC.GOV for additional guidance.  
 
 
VI. LIMITATIONS OF PROCEDURE 
 
• This protocol was optimized using Invitrogen’s Superscript III Platinum®
 
One 
Step RT-PCR Kit and both the Applied Biosystems 7500 and 7900HT Real-
Time PCR Systems.  It has not been validated with other reagent kits or 
thermocyclers, but would be expected to perform similarly with similar 
reaction conditions and other settings. 
 
• Performance of PCR amplification-based assays depends on the amount and 




VII. RECORDING / REPORTING 
 
Controls and Test results must be recorded on the applicable worksheet or log, 
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Attachment A: Primer and Probe Sets 
 
Primers/Probes  Sequence (5’>3’)  Working 
Conc. 
Lot No.  
ZaiNPTaqM1-F TGG AAA AAA CAT TAA GAG AAC ACT TGC 50µM  YYYYY 
ZaiNPTaqM1-R AGG AGA GAA ACT GAC CGG CAT 50µM  YYYYY 
ZaiNPTaqMProbe 
1* 
CA TGC CGG AAG AGG AGA CAA CTG AAG C 5µM  YYYYY 
 
*TaqMan® probes are labeled at the 5'-end with the reporter molecule 6-
carboxyfluorescein (FAM) and with the quencher, Blackhole Quencher 1 (BHQ1) 
(Biosearch Technologies, Inc., Novato, CA) at the 3'-end.  
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/ Negative) Quantitative 
 1    
 2    
 3    
 4    
 5    
 
Laboratorian (name):         
Date DNA/RNA Isolated:        
Method of DNA/RNA Isolation:       
PCR Kit Lot #:         
Kit Expiration Date of LC PCR test:   
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Attachment C: How to Make Chlorine Solutions for Environmental Disinfection 
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Notification and Consultation 
 
Hospitals should follow their national and local guidance for notification and consultation for Ebola testing 
requests first. CDC may then be contacted in consultation with your Ministry of Health IHR point of contact and 
WHO to request Ebola virus testing. 
 
CDC cannot accept any specimens without prior consultation. For consultation, call the Emergency Operations 
Center at +1-770-488-7100. 
 
When Specimens Should Be Collected for Ebola Testing 
 
Ideally, specimens should be taken when a symptomatic patient reports to a health care facility and is suspected 
of having an Ebola virus exposure. However, if the onset of symptoms is less than three days, a subsequent 
specimen will be required to rule out Ebola. 
• Patients can transmit the virus once symptoms appear and through the later stages of disease, as well as 
postmortem.   
• Ebola virus can be detected in blood only after the onset of symptoms, most notably fever.  
• It may take up to three days after the onset of symptoms for the virus to reach detectable levels.  
• Virus is generally detectable by real-time RT-PCR from 3-10 days after the onset of symptoms. 
 
Preferred Specimens for Ebola Testing 
 
Specimens should include a minimum volume of 4 milliliters whole blood preserved with any of the following: 
• EDTA, or clot activator, sodium polyethanol sulfonate (SPS), or Citrate. 
 
Submit specimens for Ebola virus disease testing in plastic collection tubes. Do not submit specimens to CDC in 
glass containers. Do not submit specimens preserved in heparin tubes.  
 
Specimens should be stored and shipped at 4°C or frozen on ice packs or on dry ice.  
 
Note: Specimens other than blood (i.e. skin snips from post mortem) may be submitted after consulting with the 
CDC. For a consultation, call the Emergency Operations Center at +1-770-488-7100. 
 
Apply standard labeling for each specimen. Identify the requested test on the requisition and CDC specimen 
submission forms.  These forms are located later in this information packet in the “Shipping Information” 
section.  
 
Diagnostic Testing for Ebola Performed at CDC 
 
CDC is a WHO recognized Collaborating Center for diagnosis of Viral Hemorrhagic Fevers. Several diagnostic 
tests are available for detection of Ebola virus disease.  
• Acute infections will be confirmed using a real-time RT-PCR assay (CDC test directory code CDC -10309 
Ebola Identification).  
• Virus isolation may also be attempted.  
• Serologic testing for IgM and IgG antibodies will be completed for certain specimens and to monitor the 
immune response in confirmed Ebola virus disease patients (#CDC-10310 Ebola Serology). 
 
Lassa fever is also endemic in certain areas of West Africa and may show symptoms similar to early Ebola virus 
disease. Diagnostic testing to identify Lassa fever can also be done at CDC. 
• Diagnostic tests including but not limited to RT-PCR, antigen detection, and IgM serology may be used to 
rule out Lassa fever in Ebola virus disease-negative patients. 
 
Transporting Specimens within the Hospital / Institution 
 
In compliance with 29 CFR 1910.1030, place specimens in a durable, leak-proof secondary container for 
transport within a facility.  
 
Important: To reduce the risk of breakage or leaks, do not use any pneumatic tube system for transporting 
suspected Ebola virus disease specimens.  
 
Packaging and Shipping Clinical Specimens to CDC 
 
Do not open collection tubes or aliquot specimens collected for Ebola virus disease testing.  
 
Package specimens in their collection tubes for shipment following the basic triple packaging system: 
• a primary receptacle (a sealable specimen bag) wrapped with absorbent material, 
• placed inside a secondary receptacle (watertight, leak-proof), and then 
• placed in turn in an outer shipping package  (see IATA drawing below) 
 
The Submission Process 
 
Contact your Ministry of Health IHR point of contact and WHO, in consultation with CDC, to determine the 
proper category for shipment and packaging requirements. Packaging requirements should be based on clinical 
history and assessment of patient by the local Ministry of Health, WHO and CDC.  A United States Public Health 
Service Import permit will be supplied by CDC if testing and shipment of specimens to CDC is required.   
 
Note: National guidelines may differ; consult your country’s guidelines before shipping. 
 
Information on shipping and tracking is available at www.cdc.gov/ebola.  
 
LOW / VERY LOW RISK EXPOSURE
Does patient meet ANY of following  within 21 days 
before symptom onset?
• Providing patient care (without known high-risk  
exposure) or casual contact with EVD patients in 
health care facilities in outbreak-affected 
countries*?
• Household member or casual contact**of an EVD 
patient?
• Direct handling of bats, rodents, or primates in 
endemic countries?
HIGH RISK EXPOSURE
Does patient meet ANY of following  within 21 days before 
symptom onset?
• Direct exposure to body fluids of EVD patient?
• Direct care of a confirmed or suspected EVD patient  
without personal protective equipment (PPE)?
• Laboratory worker processing body fluids in the 
outbreak-affected area* without appropriate PPE or 
standard laboratory biosafety precautions?
• Participation in funeral rites or body preparation in the 
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If no other DX
DEFINITIONS
Fever: 
• Defined as ≥ 101.5 ° F/38.6°C
Abnormal Blood Work:




• Intense  weakness
• Muscle pain
• Headache and sore throat
• Vomiting
• Diarrhea
• Impaired kidney & liver function
• Internal or external bleeding
DECISION GUIDE FOR CDC CONSULTATION AND DIAGNOSTIC EBOLA VIRUS DISEASE (EVD) TESTING
Initial consultation should be established 
between the attending physician, MoH, WHO 
and CDC
Testing Indicated
Call CDC (001-770-488-7100) for consultation 
and submission information
Optional Test, by clinical decision , if no other 
diagnosis identified 
Call CDC (001-770-488-7100) for consultation if 
questions
*Outbreak updates and affected countries found at: http://www.cdc.gov/vhf/ebola/outbreaks/guinea/index.html










SPECIMENS RECEIVED WITHOUT PRIOR CONSULTATION 
WILL NOT BE TESTED. TESTING MAY BE DELAYED IF  




If no other DX
SPECIMENS RECEIVED WITHOUT PRIOR 
CONSULTATION WILL NOT BE TESTED. TESTING 
MAY BE DELAYED IF  TRACKING INFORMATION 
IS NOT PROVIDED. 
Decision to Test or Ship
Consultation between Clinician, MoH, WHO and CDC
Contact CDC EOC
For Shipping Instructions 
CDC Consultation
See Documents
Complete IATA Form and Relevant
CDC/VSPB Specimen Forms
IATA Compliant Triple Package
Category A Style





















** NO SPECIMENS ACCEPTED WITHOUT PRIOR CONSULTATION ** 
Call (404) 639-1510 or (404) 639-1115 for authorization to ship specimens. 
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Instructions for submitting Diagnostic Specimens to CDC’s Viral Special Pathogens Branch 
1 Label all samples with the following information: Patient’s name or ID number, specimen ID number, date of collection 
2 For PCR/virus isolation, submit: For serologic testing, submit:
referred: whole blood (purple, yellow, or blue top Serum (red top tube or serum separator)
tube), fresh frozen tissue. Serum can also be used if -- or --
only sample available. Whole blood (purple, green, or blue top tube) 
 Minimum sample volume: 4 mL Minimum sample volume: 4 mL 
Fresh frozen tissues should be at least 1 cm3, except refrigerated or frozen on ice 
for biopsies. packs. 
rozen on dry ice in a plastic 
tube. Do not freeze glass tubes. 
Immunohistochemistry, submit: 
be submitted: 
referred: lung, kidney, liver, spleen 
Other tissues can be submitted if available. 
was not recent. 
temperature. Do not freeze. 
 An autopsy or surgical report must accompany the 
specimen. 
Specimen packaging requirements: 
contact your state health department for approval to submit a specimen to CDC for laboratory testing. 
ackage in accordance with the International Air Transport Association, regulations to prevent leakage. (Seehttps://www.iata.org/publications/dgr/ ages/manuals.aspx 
and http://www.hercenter.org/regsandstandards/Transporting_Infectious_Substances_Safely.pdf) 
Include the following information on the Diagnostic Specimen Submission Form: your name, the patient’s name, test(s) requested, date of collection, laboratory or 
accession number, and the type of specimen being shipped. 
On the outside of the box, specify how the specimen should be stored: Frozen, Refrigerated, or Do Not Refrigerate. 
Send specimens by overnight courier. International submitters should consider door-to-door shipment via air transport to expedite specimen delivery to CDC. 
Be sure to check  ‘Saturday Delivery’  if desired. 
Email the tracking number to the Viral Special athogens Branch. 
4 
The following forms should be completed for each patient: 
Specimen Submission Form 
Diagnostic Specimen Submission Form, on following page. 
For Hantavirus ulmonar y Syndrome testing,  also submit the Case Report Form
copy of all above Forms with the specimens. 
3 
guidelines may di!er and state or local health departments should be consulted prior to shipping. 
5 HOW TO SUBMIT THE SPECIMENS AND FORMS TO CDC 
Specimen submission address (if approved by state):
Centers for Disease Control and Prevention 
ATTN STAT LAB: B, Unit #70 
1600 Clifton Road NE 
Atlanta, GA 30333  
Form submission by email: 
Hit the ‘Send to CDC’ button at the bottom right of page 
2. Your computer will generate an email containing the 
completed information. Hit the ‘Send’ button in your email 
application to send the email to CDC. Acknowledgement 
of receipt is not provided. 
Form submission by fax: 
(404) 639-1118 or (404) 639-1509 
** NO SPECIMENS ACCEPTED WITHOUT PRIOR CONSULTATION ** 
Call (404) 639-1510 or (404) 639-1115 for authorization to ship specimens. 
Viral Special Pathogens Branch Diagnostic Specimen Submission Form 
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Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the 




IATA Packing Instructions 620 & 954
Overpack Markings and Labels
2014
ACCEPTANCE CHECKLIST FOR DRY ICE (Carbon Dioxide, solid)
(For use when a Shipper's Declaration
for Dangerous Goods is not required)
A checklist is required for all shipments of dangerous goods (9.1.4) to enable proper acceptance checks to be made. The
following example checklist is provided to assist shippers and carriers with the acceptance of dry ice when packaged on
its own or with non-dangerous goods.
Is the following information correct for each entry?
DOCUMENTATION
YES NO* N/A
The Air Waybill contains the following information in the “Nature and Quantity of Goods” box (8.2.3)
1. The UN Number “1845”, preceded by the prefix “UN”.................................................................................. # #
2. The words “Carbon dioxide, solid” or “Dry ice” ............................................................................................. # #
3. The number of packages of dry ice (may be in the pieces field of the AWB when they are the only
packages in the consignment) ...................................................................................................................... # #
4. The net quantity of dry ice in kilograms ........................................................................................................ # #
Note: The packing instruction “954” is optional.
Quantity
5. The quantity of dry ice per package is 200 kg or less [4.2] .......................................................................... # #
PACKAGES AND OVERPACKS
6. The number of packages containing dry ice delivered as shown on the Air Waybill.................................... # #
7. Packages are free from damage and in a proper condition for carriage ...................................................... # #
8. The packaging conforms with Packing Instruction 954 and the package is vented to permit the release
of gas ............................................................................................................................................................ # #
Markings & Labels
9. The UN number “1845” preceded by prefix “UN” [7.1.4.1(a)] ....................................................................... # #
10. The words “Carbon dioxide, solid” or “Dry ice” [7.1.4.1(a)]........................................................................... # #
11. Full name and address of the shipper and consignee [7.1.4.1(b)] ............................................................... # #
12. The net quantity of dry ice within each package [7.1.4.1(d)] ........................................................................ # #
13. Class 9 label affixed [7.2.3.9]........................................................................................................................ # #
14. Irrelevant marks and labels removed or obliterated [7.1.1(b); 7.2.1(a)]........................................................ # # #
Note: The Marking and labelling requirements do not apply to ULDs containing dry ice
For Overpacks
15. Packaging Use markings and hazard and handling labels, as required must be clearly visible or
reproduced on the outside of the overpack [7.1.7.1, 7.2.7] .......................................................................... # # #
16. The word “Overpack” marked if markings and labels are not visible [7.1.7.1].............................................. # # #
17. The total net quantity of carbon dioxide, solid (dry ice) in the overpack [7.1.7.1]......................................... # # #
Note: The Marking and labelling requirements do not apply to ULDs containing dry ice
State and Operator Variations





* IF ANY BOX IS CHECKED “NO”, DO NOT ACCEPT THE SHIPMENT AND GIVE A DUPLICATE COPY OF THIS
COMPLETED FORM TO THE SHIPPER.
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Key messages for infection prevention and control (IPC) to be applied 
in health care
ñ  Strengthen and carefully apply standard precautions when providing care to ALL patients regardless of the
signs and symptoms they present with.
ñ  Isolate suspected or confirmed hemorrhagic fever (HF) cases in single isolation rooms or cohort them in
specific confined areas while rigorously keeping suspected and confirmed cases separate. Assure restricted
access to these areas and dedicated equipment.
ñ  Exclusively assign clinical and non-clinical personnel to HF patient care areas.
ñ  Ensure that prior to entering the patient isolation rooms/areas, all visitors and health-care workers
rigorously use personal protective equipment (PPE) and perform hand hygiene as indicated in this document.
PPE should include at least: gloves, gown, boots/closed shoes with overshoes (and mask and eye protection
for splashes).
ñ  Ensure safety of injections and phlebotomy procedures and management of sharps.
ñ  Ensure regular and rigorous environmental cleaning, decontamination of surfaces and equipment,
and management of soiled linen and of waste as indicated in this document.
ñ  Ensure safe processing of laboratory samples from suspected or confirmed patients with HF.
ñ  Ensure that the IPC measures indicated in this document are followed while handling dead bodies or
human remains of suspected or confirmed patients with HF for post-mortem examination and burial
preparation.
ñ  Promptly evaluate, care for, and if necessary, isolate health-care workers or any person exposed to blood
or body fluids from suspected or confirmed patients with HF.
5 Introduction
INTRODUCTION
This document provides a summary of infection prevention and control (IPC) measures for those providing
direct and non-direct care to patients with suspected or confirmed cases of Filovirus haemorrhagic fever (HF),
including Ebola or Marburg haemorrhagic fevers, in health-care facilities (HCFs). It also includes some
instructions and directions for those managing the implementation of IPC activities. These IPC measures
should be applied not only by health-care professionals but by anyone in direct contact with patients (e.g.,
visitors, family members, volunteers), as well as by those not in contact with patients but potentially exposed
the virus through contact with the environment (e.g., c leaners, laundry, house-keepers, security).
This document represents a rapid update of the WHO 2008 “Interim Infection Control Recommendations for
Care of Patients with Suspected or Confirmed Filovirus (Ebola, Marburg) Hemorrhagic Fever”. This update is
based upon review of WHO and other international reference documents being used in the current Ebola
outbreak (see references) and international experts’ consensus.
Ebola is a severe illness caused by Ebola virus. (http://www.who.int/csr/disease/ebola/en/). It is highly
infectious, rapidly fatal, with a death rate of up to 90%, but can be prevented. It is spread through direct
contact with body fluids like blood, saliva, urine, sperm, etc. of an infected person and by contact with
contaminated surfaces or equipment, including linen soiled by body fluids from an infected person. The Ebola
virus can be relatively easily eliminated with heat, alcohol-based products, and sodium hypochlorite (bleach)
or calcium hypochlorite (bleaching powder) at appropriate concentrations. 
If carefully implemented, IPC measures will reduce or stop the spread of the virus and protect health-care
workers (HCWs) and others. It is advised that in the affected area(s), a subcommittee for clinical case
management is established;1 as part of this committee, a coordinator(s) should be named to oversee
adherence to the IPC measures in each HCF and acts as a focal person to coordinate activities and advise. If
available, this person should be the professional in charge of IPC in the HCF.
Case identification and detection, contact tracing and patient clinical assessment and management are not
the object of this Guidance document and instructions can be found elsewhere.1, 2 However, regarding IPC
measures to be implemented during interviews for contact tracing and case finding in the community, the
following principles should be kept in mind: 1) shaking hands should be avoided; 2) a distance of more than
one metre (about 3 feet) should be maintained between interviewer and interviewee; 3) PPE is not required if
this distance is assured and when interviewing asymptomatic individuals (e.g., neither fever, nor diarrhoea,
bleeding or vomiting) and provided there will be no contact with the environment, potentially contaminated
with a possible/probable case; 4) it is advisable to provide workers undertaking contact tracing and case
finding in the community with alcohol-based hand rub solutions and instructions to appropriately perform
hand hygiene.
1. GENERAL PATIENT CARE
Strengthen and carefully apply standard precautions 2-4 (Annex 1) when providing care to ALL patients
regardless of the signs and symptoms they present with. This is especially important because the initial
manifestations of HF may be non-specific. Hand hygiene is the most important measure. Gloves should be worn
for any contact with blood or body fluid. Medical mask and goggles or face shield should be used if there is any
potential for splashes of blood or body fluids to the face, and cleaning of contaminated surfaces is paramount.
2. DIRECT PATIENT CARE (FOR SUSPECTED OR CONFIRMED
PATIENTS WITH HF)
PATIENT PLACEMENT, STAFF ALLOCATION, VISITORS
ñ  Put suspected or confirmed cases in single isolation rooms with an adjoining dedicated toilet or latrine,
showers, sink equipped with running water, soap and single-use towels, alcohol-based hand rub dispensers,
stocks of personal protective equipment (PPE), stocks of medicines, good ventilation, screened windows,
doors closed and restricted access;2 if isolation rooms are unavailable, cohort these patients in specific
confined areas while rigorously keeping suspected and confirmed cases separate and ensure the items
listed here for isolation rooms are readily available. Make sure that there is at least 1 meter (3 feet) distance
between patient beds.
ñ  Ensure that clinical and non-clinical personnel are assigned exclusively to HF patient care areas and that
members of staff do not move freely between the HF isolation areas and other clinical areas during the
outbreak.
ñ  Restrict all non-essential staff from HF patient care areas.
ñ  Stopping visitor access to the patient is preferred, but if this is not possible, limit their number to include
only those necessary for the patient’s well-being and care, such as a child’s parent.
ñ  Do not allow other visitors to enter the isolation rooms/areas and ensure that any visitors wishing to
observe the patient do so from an adequate distance (approximately 15 m or 50 feet).
ñ  Before allowing visitors to HF patients to enter the HCF, screen them for signs and symptoms of HF.
HAND HYGIENE, PERSONAL PROTECTIVE EQUIPMENT (PPE) AND OTHER PRECAUTIONS 
ñ  Ensure that all visitors use PPE and perform hand hygiene as indicated below and are provided with related
instructions (Annexes 2, 3, 4) 2, 5, 6 prior to entry into the isolation room/area.
ñ  Ensure that all HCWs (including aides and cleaners) wear PPE (Annexes 2, 3, 4) as appropriate according to
the expected level of risk before entering the isolation rooms/areas and having contacts with the patients
and/or the environment.
ñ  Personal clothing should not be worn for working in the patient areas. Scrub or medical suits should be
worn.
ñ  Carefully apply the following precautions 3, 7 to avoid any possible unprotected direct contact with blood
and body fluids when providing care to any patient with HF, including suspected cases:
! Perform hand hygiene:
ñ  before donning gloves and wearing PPE on entry to the isolation room/area, 
ñ  before any clean/aseptic procedures being performed on a patient, 
ñ  after any exposure risk or actual exposure with the patient’s blood and body fluids, 
ñ  after touching (even potentially) contaminated surfaces/items/equipment in the patient’s
surroundings, 
ñ  and after removal of PPE, upon leaving the care area. 
Hand hygiene should be performed within the isolation rooms/areas every time it is needed according to
the above indications during care to a patient, along with change of gloves. When caring for patients in
the same room, it is essential to organize the complete care to each patient before moving to the next
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and to perform hand hygiene between touching the patients. Furthermore, neglecting to perform hand
hygiene after removing PPE will reduce or negate any benefits of the protective equipment.
To perform hand hygiene, either use an alcohol-based hand rub or soap and running water applying the
correct technique recommended by WHO (Annex 3).5 Always perform hand hygiene with soap and
running water when hands are visibly soiled. Alcohol-based hand rubs should be made available at every
point of care (at the entrance and within the isolation rooms/areas) and are the standard of care.
However, if alcohol-based hand rubs are unavailable, perform hand hygiene with soap and running water
every time necessary according to the above indications. Alcohol-based hand rubs can be produced
locally at the HCF level by following the WHO recommendations and instructions (Annex 5).8
! Before entering the isolation rooms/areas, wear PPE in dedicated changing zone as follows and
according to the sequence illustrated in Annex 2:
ñ  Correctly sized gloves (non-sterile examination gloves) when entering the patient care area (Annex
3).6 Consider changing gloves if heavily soiled with blood or any body fluids while providing care to
the same patient (perform careful hand hygiene immediately after removal). Always change gloves
and perform hand hygiene immediately after removal, when moving from one patient to another
while caring for patients in the same room. Consider double gloving when the quality of gloves
appears to be poor (e.g., if holes and tears form rapidly during use).
ñ  A disposable, impermeable gown to cover clothing and exposed skin. 
ñ  A medical mask and eye protection (eye visor or goggles or face shield) to prevent splashes to the
nose, mouth and eyes. 
ñ  Closed, puncture and fluid resistant shoes (e.g. rubber boots) to avoid contamination with blood or
other body fluids or accidents with misplaced, contaminated sharp objects. If boots are not
available, overshoes should be used but these must be removed while still wearing gloves and with
caution to avoid hand contamination (Annex 2). 
! When undertaking any strenuous activity (e.g. carrying a patient) or tasks in which contact with blood
and body fluids is anticipated (e.g., the patient has symptoms like diarrhoea, bleeding or vomiting
and/or the environment could be contaminated with blood or body fluids), in addition to the above-
mentioned PPE also use double gloving, and wear a waterproof apron over the gown if for any reasons
your gown is non-impermeable, and disposable overshoes and leg coverings, if boots are not available.
! Avoid aerosol-generating procedures if possible. Wear a respirator (FFP2 or EN certified equivalent or
US NIOSH-certified N95), if any procedures that stimulate coughing or promote the generation of
aerosols (e.g., aerosolized or nebulized medication administration, diagnostic sputum induction,
bronchoscopy, airway suctioning, endotracheal intubation, positive pressure ventilation via face mask)
is planned to be performed.7
! Before exiting the isolation room/area, carefully remove and dispose of PPE (including boots) into
waste containers and perform hand hygiene (Annex 2).2
! When removing PPE, be careful to avoid any contact between the soiled items (e.g. gloves, gowns) and
any area of the face (i.e. eyes, nose or mouth) or non-intact skin.
! Do not recycle any single-use disposable PPE. However, if the decontamination of goggles and visors
is necessary, it is essential that these items should be cleaned with water (± detergent) to remove any
organic matter and then immersed fully in 1000 ppm [parts per million] of available chlorine (0.5%) for
a minimum of 30 mins (preferably overnight) for decontamination. After decontamination, they should
be thoroughly rinsed with water (to remove irritating hypochlorite residues and salt deposits) before re-
use. The wipes used for the initial cleaning should be treated as infectious waste; the disinfectant can
be safely poured down a sink or drain.9
! Carefully clean and decontaminate reusable equipment (as described below).
! Rigorously use dedicated equipment (e.g. stethoscopes) for each patient. However, if this is not
possible, decontaminate the items between each patient contact. For instance, if the stethoscope has
to be used on different patients, it is essential that the full stethoscope (i.e. staff hand contact as well
as patient contact surfaces) be thoroughly cleaned first with water and soap using appropriate PPE to
remove organic matter and then wiped with alcohol.9 All waste generated during this decontamination
process should be treated as infectious waste (see below).
7 Direct patient care (for suspected or confirmed patients with HF)
! Items and equipment should not be moved between isolation rooms/areas and other areas of the HCF,
unless they are appropriately discarded and disposed. For instance, the patient charts and records
should be kept outside the isolation rooms/areas to avoid their contamination.
INJECTION SAFETY AND MANAGEMENT OF SHARPS
ñ  Each patient should have exclusively dedicated injection and parenteral medication equipment which
should be disposed of at the point of care. Syringes, needles or similar equipment should never be reused.
ñ  Limit the use of needles and other sharp objects as much as possible.
ñ  Limit the use of phlebotomy and laboratory testing to the minimum necessary for essential diagnostic
evaluation and patient care.9
ñ  If the use of sharp objects cannot be avoided, ensure the following precautions are observed:10
- Never replace the cap on a used needle.
- Never direct the point of a used needle towards any part of the body.
- Do not remove used needles from disposable syringes by hand, and do not bend, break or otherwise
manipulate used needles by hand.
- Dispose of syringes, needles, scalpel blades and other sharp objects in appropriate, puncture-resistant
containers.
ñ  Ensure that puncture-resistant containers for sharps objects are placed as close as possible to the
immediate area where the objects are being used (‘point of use’) to limit the distance between use and
disposal, and ensure the containers remain upright at all times. If the sharps container is far, never carry
sharps in your hand but place them all in a kidney dish or similar to carry to the sharps container. 
ñ  Ensure that the puncture-resistant containers are securely sealed with a lid and replaced when 3/4 full.
ñ  Ensure the containers are placed in an area that is not easily accessible by visitors, particularly children
(e.g. containers should not be placed on floors, or on the lower shelves of trolleys in areas where children
might gain access).
3. ENVIRONMENTAL CLEANING AND MANAGEMENT OF LINEN
PPE
ñ  Wear heavy duty/rubber gloves, impermeable gown and closed shoes (e.g. boots) when cleaning the
environment and handling infectious waste.
ñ  In addition, wear facial protection (mask and goggle or face shield) and overshoes if boots are unavailable,
when undertaking cleaning activities with increased risk of splashes or in which contact with blood and
body fluids is anticipated (e.g., cleaning surfaces heavily soiled with vomit or blood or cleaning areas
closer than 1 meter/3 feet from a patient with symptoms like diarrhoea, bleeding or vomiting, etc.).
CLEANING PROCESS
ñ  Environmental surfaces or objects contaminated with blood, other body fluids, secretions or excretions should
be cleaned and disinfected as soon as possible using standard hospital detergents/disinfectants (e.g. a 0.5%
chlorine solution or a solution containing 1 000 ppm available free chlorine)11. Application of disinfectants
should be preceded by cleaning to prevent inactivation of disinfectants by organic matter.
ñ  If locally prepared, prepare cleaning and disinfectant solutions every day. Change cleaning solutions and
refresh equipment frequently while being used during the day, as they will get contaminated quickly (follow
your hospital protocols if available). For preparing chlorine-based solutions, see instructions in Annex 6.
ñ Clean floors and horizontal work surfaces at least once a day with clean water and detergent. Cleaning
with a moistened cloth helps to avoid contaminating the air and other surfaces with air-borne particles.
Allow surfaces to dry naturally before using them again.
ñ  Dry sweeping with a broom should never be done. Rags holding dust should not be shaken out and surfaces
should not be cleaned with dry rags. 
ñ  Cleaning should always be carried out from “clean” areas to “dirty” areas, in order to avoid contaminant
transfer.
ñ  Do not spray (i.e. fog) occupied or unoccupied clinical areas with disinfectant. This is a potentially
dangerous practice that has no proven disease control benefit.
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MANAGEMENT OF LINEN
ñ  Linen that has been used on patients can be heavily contaminated with body fluids (e.g. blood, vomit) and
splashes may result during handling. When handling soiled linen from patients, use gloves, gown, closed
shoes (e.g., boots) and facial protection (mask and goggle or face shield).
ñ  Soiled linen should be placed in clearly-labelled, leak-proof bags or buckets at the site of use and the
container surfaces should be disinfected (using an effective disinfectant) before removal from the isolation
room/area. If there is any solid excrement such as faeces or vomit, scrap off carefully using a flat firm
object and flush it down the toilet or in the sluice before linen is placed in its container. If the linen is
transported out of the patient room/area for this procedure it should be put in a separate containter – it
should never be carried against the body.
ñ  Linen should be then transported directly to the laundry area in its container and laundered promptly with
water and detergent. 
ñ  For low-temperature laundering, wash linen with detergent and water, rinse and then soak in 0.05%
chlorine for approximately 30 minutes. Linen should then be dried according to routine standards and
procedures.
ñ  Washing contaminated linen by hand should be discouraged. However, if washing machines are not
available or power is not ensured, take the soiled linen out of the container and empty it into a large drum
container of hot water and soap. Soak the linen in this drum and make sure it is totally covered with water.
Use a stick to stir; then throw out the water and refill the drum with clean water and add bleach 1000ppm
and allow to soak for 10 –15 minutes. Remove the linen and then rinse in clean water. Remove excess
water and spread out to dry. Avoid as much splashing as possible.
ñ  If safe cleaning and disinfection of heavily soiled linen is not possible or reliable, it may be prudent to burn
the linen to avoid any unnecessary risks to individuals handling these items.
4. WASTE MANAGEMENT
PPE
ñ  Wear heavy duty/rubber gloves, impermeable gown, closed shoes (e.g. boots) and facial protection
(mask and goggle or face shield), when handling infectious waste (e.g. solid waste or any secretion or
excretion with visible blood even if it originated from a normally sterile body cavity). Goggles provide
greater protection than visors from splashes that may come from below when pouring liquid waste from a
bucket. Avoid splashing when disposing of liquid infectious waste.
WASTE MANAGEMENT PROCEDURES
ñ  Waste should be segregated at point of generation to enable appropriate and safe handling.
ñ  Sharp objects (e.g. needles, syringes, glass articles) and tubing that has been in contact with blood or body
fluids should be placed inside puncture resistant waste containers (as described above). These should be
located as close as practical to the patient care area where the items are used, similarly in laboratories.
ñ  Collect all solid, non-sharp, infectious waste using leak-proof waste bags and covered bins. Bins should
never be carried against the body (e.g. on the shoulder).
ñ  Waste should be placed in a designated pit of appropriate depth (e.g. 2 m or about 7 feet) and filled to a
depth of 1–1.5 m (or about 3–5 feet). After each waste load, the waste should be covered with a layer of
soil 10 –15 cm deep.
ñ  An incinerator may be used for short periods during an outbreak to destroy solid waste. However, it is
essential to ensure that total incineration has taken place. Caution is also required when handling flammable
material and when wearing gloves due to the risk of burn injuries if gloves are ignited.
ñ  Placenta and anatomical samples should be buried in a separate pit.
ñ  The area designated for the final treatment and disposal of waste should have controlled access to prevent
entry by animals, untrained personnel or children. 
ñ  Waste, such as faeces, urine and vomit, and liquid waste from washing, can be disposed of in the sanitary
sewer or pit latrine. No further treatment is necessary.
9 Waste management
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Table. Summary table for implementation of IPC best practices during
direct patient care and related activities
What?
Create isolation rooms or areas.
Restrict all non-essential 
staff from HF patient care
rooms/areas.
Limit the number of visitors
allowed access to the patient.
Ensure that all staff and visitors




- Identify single rooms and
prioritise these for patients with
known or suspected Ebola virus.
- Refer to guidance on setting up
an isolation area.2
- Ensure that clinical and non-
clinical personnel are assigned
exclusively to patient care areas
and that members of staff do
not move freely between these
areas and other clinical areas
during the outbreak.
- Cohort staff between areas 
with suspected and those with
confirmed HF patients.
- Use signage to alert restrictions
of staff.
- Maintain a log of persons
entering the room.
- Use signage and other
communications to alert
restrictions of visitors. Make
simple messages understandable
for the public but also be
careful to avoid stigmatization. 
- Maintain a log of persons
entering the room.
- Ensure the equipment is always
available and promptly at 
the isolation rooms/areas entry.
- Provide staff and visitors with
instructions on the use and
correct removal of PPE through
training and reminder posters.
Who is responsible?
- Coordinator or IPC staff to
identify areas/rooms for patient
placement.
- Health workers to adhere to
recommendations and report to
the coordinator when a patient
is not placed in an isolation
room/area.
- Coordinator and/or IPC staff.
- Coordinator and/or IPC staff
- Involve patient or community
representatives, if available. 
- Health workers to adhere 
to recommendations and report
to the coordinator when they
are not followed.
- Coordinator and/or IPC staff
- Involve patient or community
representatives, if available. 
- Health workers to adhere 
to recommendations and report
to the coordinator when they
are not followed.
- Another staff member should 
be assigned to supervise 
the sequence of putting on and
removing PPE by his/her
colleague.
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What?
Ensure that all staff and visitors
perform hand hygiene according
to the above recommendations.
These hand hygiene actions
should be performed when
recommended even if PPE is
worn.
Limit the use of needles and
other sharp objects as much as
possible. If this cannot be
avoided see instructions in 
the text.
Dispose of needles and other
sharp objects safely.
Create system of safe
management of waste and linen.
Limit the use of phlebotomy and
laboratory testing to the minimum
necessary for essential diagnostic
evaluation and patient care.
Only take a patient out of their
room/care area if they are free of
virus, or for essential, life-saving
tests.
Undertake cleaning of the
environment and patient care
equipment safely following
recommendations in the text.
How?
- Provide staff and visitors with
instructions on the importance 
of hand hygiene best practices
through training and reminder
posters.
- Ensure continuous availability
of alcohol-based handrub 
and soap, water and single-use
towels at the isolation
room/areas entry and at 
the point of care.
- Provide staff and carers with
instructions on the essential use
of needles and sharps through
training and reminder posters.
- Ensure the equipment is
available to do this.
- Provide staff and carers with
instructions on the safe disposal
of sharps through training and
reminder posters. 
- Ensure the equipment is
available to do this.
- Provide staff and visitors/carers
with instructions on the safe
management and disposal 
of waste and linen through
training and reminder posters. 
- Ensure the equipment is
available to do this.
- Provide staff with training and
visual instructions on the need
for essential phlebotomy and
lab testing.
- Provide staff with training and
visual instructions on the
appropriate times to take the
patient from their care area and
on precautions to take.
- Provide staff and visitors/carers
with instructions on cleaning
through training and reminder
posters.




- Coordinator and/or IPC staff.
- Involve patient or community
representatives, if available.
- Health workers to adhere 
to recommendations and report
to the coordinator when they
are not followed.
- Health workers to adhere to
recommendations.
- Health workers to adhere 
to recommendations and report
to the coordinator when they 
are not followed.
- Health workers to adhere 
to recommendations and 
report to the coordinator when
they are not followed.
- Health workers to adhere 
to recommendations.
- Health workers to adhere 
to recommendations and report
to the coordinator when they 
are not followed.
- Health workers to adhere 
to recommendations and 
report to the coordinator when
they are not followed.
IPC = infection prevention and control; PPE = personal protective equipment
5. NON-PATIENT CARE ACTIVITIES (FOR SUSPECTED OR CONFIRMED
PATIENTS WITH HF)
A. DIAGNOSTIC LABORATORY ACTIVITIES
ñ  For procedures to safely collect blood or other samples from persons suspected or confirmed to be
infected, follow the instructions provided by WHO.9
ñ  All laboratory sample processing must take place under a safety cabinet or at least a fume cabinet with
exhaust ventilation. Do not carry out any procedure on the open bench. 
ñ  Activities such as micro-pipetting and centrifugation can mechanically generate fine aerosols that might
pose a risk of transmission of infection through inhalation as well as the risk of direct exposure.
ñ  Laboratory personnel handling potential HF clinical specimens should wear closed shoes with overshoes or
boots, gloves, a disposable, impermeable gown, eye protection or face shields, and particulate respirators
(e.g., FFP2, or EN certified equivalent, or US NIOSH-certified N95) , or powered air purifying respirators
(PAPR) when aliquotting, performing centrifugation or undertaking any other procedure that may generate
aerosols.
ñ  When removing PPE, avoid any contact between the soiled items (e.g. gloves, gowns) and any area of the
face (i.e. eyes, nose or mouth).
ñ  Do not hang up the apron or gown for reuse- discard immediately.
ñ  Perform hand hygiene immediately after the removal of PPE used during specimen handling and after any
contact with potentially contaminated surfaces even when PPE is worn.
ñ  Place specimens in clearly-labelled, non-glass, leak-proof containers and deliver directly to designated
specimen handling areas.
ñ  Disinfect all external surfaces of specimen containers thoroughly (using an effective disinfectant) prior to
transport.
B. MOVEMENT AND BURIAL OF HUMAN REMAINS
ñ  The coordinator and/or the infection prevention and control staff should be consulted for any decision
making on movement and burial of human remains.
ñ  For this topic, see also the WHO “Interim manual - Ebola and Marburg virus disease epidemics:
preparedness, alert, control, and evaluation”.1
ñ  The handling of human remains should be kept to a minimum. The following recommendations should be
adhered to in principle, but may need some adaptation to take account of cultural and religious concerns:
- Wear PPE (impermeable gown, mask, eye protection and double gloves) and closed shoes or boots to
handle the dead body of a suspected or confirmed case of HF. Plug the natural orifices. Place the body in a
double bag, wipe over the surface of each body bag with a suitable disinfectant (e.g., 0.5% chlorine
solution) and seal and label with the indication of highly-infectious material. Immediately move the body
to the mortuary.
- PPE should be put on at the site of collection of human remains, worn during the process of collection and
placement in body bags, and should be removed immediately after. Hand hygiene should be performed
immediately following the removal of PPE.
- Remains should not be sprayed, washed or embalmed. Any practice of washing the remains in preparation
of “clean burials” should be discouraged.
- Only trained personnel should handle remains during the outbreak.
- PPE is not required for individuals driving or riding a vehicle to collect human remains, provided that drivers
or riders will not be handling a dead body of a suspected or confirmed case of HF.
- After wrapping in sealed, leak-proof material, remains should be placed inside a coffin if possible, and
buried promptly.
C. POST-MORTEM EXAMINATIONS 
ñ  The coordinator and/or the IPC staff should be consulted for any decision making on post-mortem
examinations.
ñ  Post-mortem examination of HF patient remains should be limited to essential evaluations only and should
be performed by trained personnel.
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13 Non-Patient Care Activities (for suspected or confirmed patients with HF)
ñ  Personnel examining remains should wear eye protection, mask, double gloves, disposable, impermeable
gowns, and closed shoes or boots.
ñ  In addition, personnel performing autopsies of known or suspected HF patients should wear a particulate
respirator (e.g., FFP2, or EN certified equivalent, or US NIOSH-certified N95) or a PAPR.
ñ  When removing PPE, avoid any contact between soiled gloves or equipment and the face (i.e. eyes, nose or
mouth).
ñ  Hand hygiene should be performed immediately following the removal of PPE.
ñ  Place specimens in clearly-labelled, non-glass, leak-proof containers and deliver directly to designated
specimen handling areas.
ñ  All external surfaces of specimen containers should be thoroughly disinfected (using an effective
disinfectant) prior to transport.
ñ  Tissue or body fluids for disposal should be carefully placed in clearly marked, sealed containers for
incineration.
D. MANAGING EXPOSURE TO VIRUS THROUGH BODY FLUIDS INCLUDING BLOOD
ñ  Persons including HCWs with percutaneous or muco-cutaneous exposure to blood, body fluids, secretions,
or excretions from a patient with suspected or confirmed HF should immediately and safely stop any
current tasks, leave the patient care area, and safely remove PPE. Remove PPE carefully according to the
steps indicated in this document (Annex 2) because exposure during PPE removal can be just as dangerous
for nosocomial transmission of HF. Immediately after leaving the patient care area, wash the affected skin
surfaces or the percutaneous injury site with soap and water . Accordingly, irrigate mucous membranes
(e.g. conjunctiva) with copious amounts of water or an eyewash solution, and not with chlorine solutions
or other disinfectants.  
ñ  Immediately report the incident to the local coordinator. This is a time-sensitive task and should be
performed as soon as the HCW leaves the patient care unit.
ñ  Exposed persons should be medically evaluated including for other potential exposures (e.g., HIV, HCV)
and receive follow-up care, including fever monitoring, twice daily for 21 days after the incident.
Immediate consultation with an expert in infectious diseases is recommended for any exposed person who
develops fever within 21 days of exposure.
ñ  HCWs suspected of being infected should be cared for/isolated, and the same recommendations outlined
in this document must be applied until a negative diagnosis is confirmed.
ñ  Contact tracing and follow-up of family, friends, co-workers and other patients, who may have been
exposed to Ebola virus through close contact with the infected HCW is essential.
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1. Hand hygiene1
How to perform hand hygiene:
ñ Clean your hands by rubbing them with an alcohol-
based formulation, as the preferred mean for routine
hygienic hand antisepsis if hands are not visibly soiled. 
It is faster, more effective, and better tolerated by your
hands than washing with soap and water.
ñ Wash your hands with soap and water when hands
are visibly dirty or visibly soiled with blood or other body
fluids or after using the toilet.
ñ If exposure to potential spore-forming pathogens 
is strongly suspected or proven, including outbreaks 
of Clostridium difficile, hand washing with soap and water 
is the preferred means.
Summary technique:1
ñ Hand washing (40–60 sec): wet hands and apply soap;
rub all surfaces; rinse hands and dry thoroughly with 
a single use towel; use towel to turn off faucet.
ñ Hand rubbing (20–30 sec): apply enough product to cover
all areas of the hands; rub all surfaces until dry.
Summary indications:1
1. Before touching a patient: Clean your hands before
touching a patient when approaching him/her*
2. Before clean / aseptic procedure: Clean your hands
immediately before accessing a critical site with infectious
risk for the patient (e.g. a mucous membrane, non-intact
skin, an invasive medical device)*
3. After body fluid exposure risk: Clean your hands as
soon as the task involving an exposure risk to body fluids
has ended (and after glove removal)*
4. After touching a patient: Clean your hands when 
leaving the patient’s side after having touched the patient*
5. After touching patient surroundings: Clean your hands
after touching any object or furniture when living the
patient surroundings, without having touched the patient*
2. Gloves
ñ Wear GLOVES when touching blood, body fluids,
secretions, excretions, mucous membranes, nonintact skin.
ñ Change GLOVES between tasks and procedures on the same
patient after contact with potentially infectious material.
ñ Remove THEM after use, before touching non-contaminated
items and surfaces, and before going to another patient.
Perform hand hygiene immediately after removal.
3. Facial protection (eyes, nose, and mouth)
ñ Wear (1) a surgical or procedure mask and eye protection
(eye visor, goggles) or (2) a face shield to protect mucous
membranes of the eyes, nose, and mouth during 
activities that are likely to generate splashes or sprays 
of blood, body fluids, secretions, and excretions.
4. Gown
ñ Wear to protect skin and prevent soiling of clothing 
during activities that are likely to generate splashes or
sprays of blood, body fluids, secretions, or excretions.
ñ Remove soiled gown as soon as possible, and per-form
hand hygiene.
5. Prevention of needle stick and injuries 
from other sharp instruments2
Use care when:
ñ Handling needles, scalpels, and other sharp instruments 
or devices.
6. Respiratory hygiene and cough etiquette
Persons with respiratory symptoms should apply
source control measures:
ñ Cover their nose and mouth when coughing/sneezing
with tissue or mask, dispose of used tissues and masks,
and perform hand hygiene after contact with respiratory
secretions.
Health-care facilities should:
ñ Place acute febrile respiratory symptomatic patients 
at least 1 metre (3 feet) away from others in common
waiting areas, if possible.
ñ Post visual alerts at the entrance to health-care facilities
instructing persons with respiratory symptoms to practise
respiratory hygiene/cough etiquette.
ñ Consider making hand hygiene resources, tissues and
masks available in common areas and areas used for 
the evaluation of patients with respiratory illnesses.
7. Environmental cleaning
ñ Use adequate procedures for the routine cleaning 
and disinfection of environmental and other frequently
touched surfaces.
8. Linens
Handle, transport, and process used linen 
in a manner which:
ñ Prevents skin and mucous membrane exposures 
and contamination of clothing.
ñ Avoids transfer of pathogens to other patients and 
or the environment.
9. Waste disposal
ñ Ensure safe waste management.
ñ Treat waste contaminated with blood, body fluids, 
secretions and excretions as clinical waste, in accordance
with local regulations.
ñ Human tissues and laboratory waste that is directly 
associated with specimen processing should also be 
treated as clinical waste.
ñ Discard single use items properly.
10. Patient care equipment
ñ Handle equipment soiled with blood, body fluids, 
secretions, and excretions in a manner that prevents 
skin and mucous membrane exposures, contamination 
of clothing, and transfer of pathogens to other patients
or the environment.
ñ Clean, disinfect, and reprocess reusable equipment 
appropriately before use with another patient.
ñ Cleaning used instruments.
ñ Disposing of used needles and other sharp instruments.
Annex 1. Standard Precautions in health Care – AIDE MEMOIRE
KEY ELEMENTS AT A GLANCE
1 For more details, see:1) WHO Guidelines on Hand Hygiene in Health Care, 2009, available at: http://www.who.int/gpsc/5may/tools/en/. 
2) “Hand Hygiene: Why, How & When?”, available at http://www.who.int/gpsc/5may/tools/training_education/en/
2 The SIGN Alliance at: http://www.who.int/injection_safety/sign/en/
*NOTE: Hand hygiene must be performed in all indications described regardless of whether gloves are used or not.
1 Always put on essential required PPE when handling either a suspect, probable or
confirmed case of VHF. Gather all the necessary items of the PPE beforehand.
2 The dressing and undressing of PPE should be supervised by another trained member 
of the team. These instructions should be displayed on the wall in the dressing and
undressing room. Steps to put on essential required PPE.
3 Put on the scrub suit in the changing room.
4 Put on gum boots; 
If not available, 
make sure you have 
closed, puncture 
and fluid resistant 
shoes and put on
overshoes.
Annex 2. 
Steps to put on Personal Protective Equipment (PPE)
5 Place the gown 
over the scrubs.
6 Put on face 
protection:
6a Put on a medical 
mask.
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17 Steps to put on essential required PPE
7 If you have 
any abrasions 
on your scalp or 
you have concern 
for splashing fluids,
also place a head
cover at this time.
8 Perform 
hand hygiene.
9 Put on gloves* (over cuff).
Whilst wearing PPE:
ñ Avoid touching or adjusting PPE
ñ Remove gloves if they become torn or damaged 
ñ Change gloves between patients
ñ Perform hand hygiene before donning new gloves
10 If a impermeable gown 
is not available and 
you expect to undertake
any strenuous activity 
(e.g. carrying a patient) 
or tasks in which contact 
with blood and body
fluids, place waterproof
apron over gown.
* Use double gloves if any strenuous activity (e.g. carrying a patient or handling a dead body)
or tasks in which contact with blood and body fluids are anticipated. Use heavy duty/rubber
gloves for environmental cleaning and waste management.
18
Interim Infection Prevention and Control Guidance for Care of Patients with Suspected or 
Confirmed Filovirus Haemorrhagic Fever in Health-Care Settings, with Focus on Ebola
3 Remove gown 
and gloves and roll
inside-out and dispose
of safely.
4 If wearing rubber boots,
remove them (ideally using
the boot remover) without
touching them with your
hands. Place the removed
boots into a container with
disinfectant.
6 If wearing a head
covering, remove it now
(from behind head).
7b Remove mask from
behind head.
Source: Modified from Clinical Management of Patients with Viral Haemorrhagic Fever: A pocket Guide for the 
Front-line Health Worker. World Health Organization, 2014
8 Perform hand hygiene.
5 Perform hand
hygiene.
1 Peel off plastic apron and 
dispose of safely, (if the apron 
is to be reused, place in 
a container with disinfectant)
2 If wearing protective 
overshoes, please
remove them 
with your gloves 
still on. (If wearing
gum boots, see 
step 4).
Steps to remove PPE
7 Remove face protection:
7a Remove face shield or
goggles (from behind 
head). Place eye protection
in a separate container 
for reprocessing.  OR
19 How to perform hand hygiene by hand rubbing or handwashing
Annex 3. 
How to perform hand hygiene by hand rubbing or handwashing
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Source: Hand Hygiene Posters. World Health Organization, Geneva, 2009; Available from:
http://www.who.int/gpsc/5may/tools/workplace_reminders/en/
21 Technique for donning and removing non-sterile examination gloves
Annex 4. 
Technique for donning and removing non-sterile examination gloves
Source: Glove Use Information Leaflet. World Health Organization, Geneva, 2009. Available from:
http://www.who.int/gpsc/5may/tools/training_educational/en/
22
Interim Infection Prevention and Control Guidance for Care of Patients with Suspected or 
Confirmed Filovirus Haemorrhagic Fever in Health-Care Settings, with Focus on Ebola
Annex 5. 
Guide to Local Production: Who-recommended Handrub Formulations
GUIDE TO LOCAL PRODUCTION
This is intended to guide a local producer in the actual preparation 
of the formulation.
Materials required (small volume production)
REAGENTS FOR REAGENTS FOR
FORMULATION 1: FORMULATION 2:
ñ Ethanol 96% ñ Isopropyl alcohol 99.8%
ñ Hydrogen peroxide 3% ñ Hydrogen peroxide 3%
ñ Glycerol 98% ñ Glycerol 98%
ñ Sterile distilled or boiled ñ Sterile distilled or boiled
cold water cold water
ñ 10-litre glass or plastic bottles with screw-threaded stoppers (1), or
ñ 50-litre plastic tanks (preferably in polypropylene or high density 
polyethylene, translucent so as to see the liquid level) (2), or
ñ Stainless steel tanks with a capacity of 80–100 litres 
(for mixing without overflowing) (3, 4)
ñ Wooden, plastic or metal paddles for mixing (5)
ñ Measuring cylinders and measuring jugs (6)
ñ Plastic or metal funnel
ñ 100 ml and 500 ml plastic bottles with leak-proof tops (7)
ñ An alcoholometer: the temperature scale is at the bottom 
and the ethanol concentration (percentage v/v and w/w) 
at the top (8)
NOTE
ñ Glycerol: used as humectant, but other emollients may be used 
for skin care, provided that they are cheap, widely available and miscible 
in water and alcohol and do not add to toxicity, or promote allergy.
ñ Hydrogen peroxide: used to inactivate contaminating bacterial 
spores in the solution and is not an active substance for hand antisepsis.
ñ Any further additive to both formulations should be clearly 
labelled and be non-toxic in case of accidental ingestion.
ñ A colorant may be added to allow differentiation from other 
fluids, but should not add to toxicity, promote allergy, or interfere with
antimicrobial properties. The addition of perfumes or dyes 
is not recommended due to risk of allergic reactions.
General information
Labelling should be in accordance with national guidelines 
and should include the following:
ñ Name of institution, date of production and batch number
ñ WHO-recommended handrub solution
ñ For external use only
ñ Avoid contact with eyes
ñ Keep out of the reach of children
ñ Use: Apply a palmful of alcohol-based handrub and cover all 
surfaces of the hands. Rub hands until dry.
ñ Composition: ethanol or isopropanol, glycerol and hydrogen
peroxide
ñ Flammable: keep away from flame and heat
Production and storage facilities:
ñ Production and storage facilities should ideally be
air conditioned or cool rooms. No naked flames 
or smoking should be permitted in these areas.
ñ WHO-recommended handrub formulations should
not be produced in quantities exceeding 50-litres
locally or in central pharmacies lacking specialised
air conditioning and ventilation.
ñ Since undiluted ethanol is highly flammable and
may ignite at temperatures as low as 10ÆC,
production facilities should directly dilute it to the
above-mentioned concentration. The flashpoints 
of ethanol 80% (v/v) and of isopropyl alcohol 75%
(v/v) are 17.5ÆC and 19ÆC, respectively.
ñ National safety guidelines and local legal
requirements must be adhered to the storage 






These can be prepared in 10-litre glass or plastic bottles 
with screw-threaded stoppers.
Recommended amounts of products:
FORMULATION 1: FORMULATION 2:
ñ Ethanol 96%: 8333 ml ñ Isopropyl alcohol 99.8%: 
7515 ml
ñ Hydrogen peroxide 3%: ñ Hydrogen peroxide 3%: 
417 ml 417 ml
ñ Glycerol 98%: 145 ml ñ Glycerol 98%: 145 ml
Final products:
FORMULATION 1: FORMULATION 2:
Final concentrations: Final concentrations:
ñ Ethanol 80% (v/v) ñ Isopropyl alcohol 75% (v/v)
ñ Glycerol 1.45% (v/v) ñ Glycerol 1.45% (v/v)
ñ Hydrogen peroxide ñ Hydrogen peroxide 
0.125% (v/v) 0.125% (v/v)
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1. The alcohol for the formula
to be used is poured into
the large bottle or tank up
to the graduated mark.
2. Hydrogen peroxide is
added using the
measuring cylinder.
7. Immediately divide up the solution into its 
final containers (e.g. 500 or 100 ml plastic
bottles), and place the bottles in quarantine
for 72 hours before use. This allows time 
for any spores present in the alcohol or the
new/re-used bottles to be destroyed.
3. Glycerol is added using a
measuring cylinder. As glycerol 
is very viscous and sticks to the
wall of the measuring cylinder, it
should be rinsed with some sterile
distilled or cold boiled water and
then emptied into the bottle/tank.
4. The bottle/tank is then topped up 
to the 10-litre mark with sterile
distilled or cold boiled water.
5. The lid or the screw cap is placed 
on the tank/bottle as soon as
possible after preparation, in order
to prevent evaporation.
6. The solution is mixed 
by shaking gently
where appropriate 
or by using a paddle.
Quality control
1. Pre-production analysis should be made
every time an analysis certificate is not
available to guarantee the titration 
of alcohol (i.e. local production). Verify
the alcohol concentration with the
alcoholmeter and make the necessary
adjustments in volume in the preparation
formulation to obtain the final
recommended concentration. 
3. The alcoholmeter shown 
in this information pamphlet 
is for use with ethanol; if used
to control an isopropanol
solution, a 75% solution 
will show 77% (± 1%) on the
scale at 25ÆC.
Step by step preparation: 
2. Post-production analysis 
is mandatory if either ethanol 
or an isopropanol solution 
is used. Use the alcoholmeter
to control the alcohol
concentration of the final use
solution. The accepted limits
should be fixed to ± 5% 
of the target concentration
(75%–85% for ethanol).
Source: Guide to Local Production: WHO-recommended Handrub Formulations, http://www.who.int/gpsc/5may/tools/system_change/en/
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Example I - Using Liquid Bleach
Chlorine in liquid bleach comes in different concentrations. Any concentration can be used to make
a dilute chlorine solution by applying the following formula:
% chlorine in liquid bleach
% chlorine desired 
– 1 = Total parts of water for each part bleach†
Example: To make a 0.5% chlorine solution from 3.5%† bleach:
3.5%
0.5%
– 1 = 7 – 1 = 6 parts water for each part bleach
Therefore, you must add 1 part 3.5% bleach to 6 parts water to make a 0.5% chlorine solution.
† “Parts” can be used for any unit of measure (e.g. ounce, litre or gallon) or any container used
for measuring, such as a pitcher.
† In countries where French products are available, the amount of active chlorine is usually
expressed in degrees chlorum. One degree chlorum is equivalent to 0.3% active chlorine.
Example II - Using Bleach Powder 
If using bleach powder, † calculate the amount of bleach to be mixed with each litre of water 
by using the following formula:
% chlorine desired
% chlorine in bleach powder
x 1 000 = Grams of bleach powder for each litre of water




x 1 000 = 0.0143 x 1 000 = 14.3
Therefore, you must dissolve 14.3 grams of calcium hypochlorite (bleach) powder in each litre of
water used to make a 0.5% chlorine solution.
† When bleach powder is used; the resulting chlorine solution is likely to be cloudy (milky).
Example III - Formula for Making a Dilute Solution from a Concentrated Solution
Total Parts (TP) (H2O) = % Concentrate -1
% Dilute
Example: To make a dilute solution (0.1%) from 5% concentrated solution.
Calculate TP (H2O) = 5.0%
0.1%
-1 = 50-1 = 49
Take 1 part concentrated solution and add to 49 parts boiled (filtered if necessary) water.
Source: 
AVSC International (1999). Infection Prevention Curriculum. Teacher’s Manual. New York, p.267.
Annex 6. 
How to make chlorine solutions for environmental disintection
[ ]
[ ]
[ ]
[ ]
[ ]
[ ]
